WO1999051575A1 - N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents) - Google Patents

N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents) Download PDF

Info

Publication number
WO1999051575A1
WO1999051575A1 PCT/US1999/007621 US9907621W WO9951575A1 WO 1999051575 A1 WO1999051575 A1 WO 1999051575A1 US 9907621 W US9907621 W US 9907621W WO 9951575 A1 WO9951575 A1 WO 9951575A1
Authority
WO
WIPO (PCT)
Prior art keywords
indol
ethyl
yloxy
amine
fluoro
Prior art date
Application number
PCT/US1999/007621
Other languages
French (fr)
Inventor
Richard Eric Mewshaw
Dahui Zhou
Original Assignee
American Home Products Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corporation filed Critical American Home Products Corporation
Priority to CA002327359A priority Critical patent/CA2327359A1/en
Priority to EP99915317A priority patent/EP1070050A1/en
Priority to JP2000542296A priority patent/JP2002510675A/en
Priority to AU33861/99A priority patent/AU3386199A/en
Publication of WO1999051575A1 publication Critical patent/WO1999051575A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to compounds useful for the treatment of diseases affected by disorders of the serotonin-affected neurological systems. More specifically, the present invention is directed to aryloxyethyl-indoly-alkylamine derivatives useful for the treatment of such diseases.
  • compositions which enhance neurotransmission of serotonin are useful for the treatment of many psychiatric disorders, including depression and anxiety.
  • the first generation of non-selective serotonin-affecting compounds operated
  • SSRIs selective serotonin reuptake inhibitors
  • the present invention relates to a new class of molecules which have the ability 35 to act concommitantly at the 5-HT1A autoreceptors and with the 5-HT transporter. Such compounds are therefore potentially useful for the treatment of anxiety or depression, as well as other serotonin disorders.
  • U.S. Patent No. 3,371,098 discloses sec. and tert. indolylethylamines useful as sedatives, anticonvulsants and analegesics.
  • U.S. Patent No. 5,436,264 discloses N-aryloxyalkyl-tryptamine-like compounds of the following formula as alpha- 1-adrenergic receptor antagonists for the treatment of cardiovascular disorders.
  • EP 0722 941 A2 discloses the preparation of a series of hetero-oxy alkanamines of the following formula for the treatment of depression and other disorders for which serotonin uptake inhibitors are normally used. x I
  • Japanese Patents 05255302 and 09040648 disclose the following compounds which are reported to be useful for the treatment of central nervous system-related diseases, such as anxiety and depression.
  • the compounds of the present invention invention are aminomethyl benzoxezine indoles represented by Formula I:
  • R j is hydrogen, lower alkyl, or aryl
  • R 2 is hydrogen, lower alkyl, phenyl, or substituted phenyl
  • X and Y are each, independently, hydrogen, lower alkyl, lower alkoxy, or halogen, or together combine with the carbon atoms to which they are attached to complete a cyclopentyl, cyclohexyl, phenyl, pyrrolyl, pyranyl, pyridinyl, dihydrofuranyl, furanyl, dioxanyl, oxazolyl, or isoxazolyl group;
  • Z is hydrogen, halogen, or lower alkoxy; with the proviso that when X, Y or Z represent lower alkoxy, they are not present at the ortho position; W is hydrogen, halogen, lower alkoxy, lower alkyl, cyano, or a trifluoromethyl group; and n is 2-5; or pharmaceutically acceptable salts thereof.
  • the present invention is further derived to pharmaceutical compounds containing such compounds, as well as methods for alleviating symptoms of depression comprising administering the present compounds to a patient in need thereof.
  • the compounds of the present invention are those represented by
  • R j is hydrogen, methyl or aryl
  • R 2 is hydrogen
  • X and Y are each, independently, hydrogen, halogen or lower alkoxy, or together combine with the carbon atoms to which they are attached to complete a cyclopentyl, cyclohexyl, phenyl, pyridinyl, dioxanyl, oxazolyl, furanyl or dihydrofuranyl group; - 4 -
  • Z is hydrogen, halogen or lower alkoxy; with the proviso that when X, Y or Z are lower alkoxy they are not present at the ortho position; W is hydrogen or halogen; and n is 2-4; or pharmaceutically acceptable salts thereof.
  • the compounds of the present invention are selected from the following:
  • lower alkyl and “lower alkoxy” are meant to include both straight and branched carbon chains containing 1 to 6 carbon atoms.
  • halogen is meant to include fluorine, chlorine, bromine, and iodine.
  • substituted phenyl is meant to include a phenyl moiety substituted with an alkyl, halogen, or alkoxy group.
  • aryl is meant to include aromatic radicals containing 6-12 carbon atoms.
  • the compounds of Formula I may advantageously be used in the form of the pharmaceutically acceptable acid addition salts thereof.
  • Such salts may be formed with both inorganic or organic acids, for example: fumaric, maleic, benzoic, ascorbic, pamoic, succinic, bismethylenesalicylic, methanesulfonic, ethanedisulfonic, acetic, oxalic, propionic, tartaric, salicyclic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzene-sulfonic, hydrochloric hydrobromic, sulfuric, cyclohexylsulfamic, phosphoric and nitric acids.
  • inorganic or organic acids for example: fumaric, maleic, benzoic, ascorbic, pamoic, succinic, bismethylenesalicylic, methanesulfonic, ethanedis
  • the compounds of the present invention may be prepared by any suitable method known to those skilled in the art. However, the present compounds may be advantageously prepared according to any one of Schemes 1 to 10 set forth below. In the Schemes, the intermediate compounds discussed hereinafter are identified in parenthesis. The compound produced in each of Schemes 1 to 10 is identified with reference to the appropriate, corresponding Example.
  • the fumarate salt was prepared in ethanol: mp 121.5 -122°C: Elemental analysis for C I6 H 19 NO 2 » C 4 H 4 O 4
  • triphenylphosphine 2.6 g, 9.9 mmol
  • 2-chloroethanol 2-chloroethanol
  • DIAD diisopropyl azidodicarbimide
  • 6-Fluorochroman-8-carbaldehyde To a solution of 6-fluorochroman (0.7 g, 4.6 mmol) in anhydrous methylene chloride (20 ml) was added TiCl 4 (1.57 g, 8.3 mmol) and ⁇ , ⁇ '-dichloromethyl methyl ether (0.53 g, 4.6 mmol) slowly at 0°C. The reaction was allowed to reach room temperature slowly and stirred for 16 hours. The reaction mixture was poured into ice- water, extracted with methylene chloride (3 x 100 ml), washed with saturated sodium carbonate (5 x 150 ml) and brine (3 x 100ml).
  • This compound was prepared in the manner described for 45(a) above by replacing 4-indanol with 5,6,7,8-tetrahydro-l-naphthol (4 g, 0.027 mol) ) in 46% yield (2.57 g) as a clear oil.
  • This compound was prepared in the manner described for 45(a) above by replacing 4-indanol with 1-naphthol (5 g, 0.035 mol) ) in 82% yield (6.34 g) as a clear oil.
  • the oxalate salt was prepared in ethanol: mp 185-188°C Elemental analysis for C 19 H 20 F 2 N 2 O 2 » C 2 H 2 O 4
  • the oxalate salt was prepared in ethanol: mp 188-189°C Elemental analysis for C 19 H 21 FN 2 O 2 « C 2 H 2 O 4 « 0.25H 2 O Calc'd C, 59.04; H, 5.63; N, 6.62
  • the oxalate salt was prepared in ethanol: mp 197.5-198.5°C Elemental analysis for C 20 H 22 N 2 O 3 »C 2 H 2 O 4
  • the fumarate salt was prepared in isopropanol: mp 189.5-190.5°C
  • the oxalate salt was prepared in ethanol: mp 213-214°C
  • the oxalate salt was prepared in isopropanol: mp 214-215°C
  • the oxalate salt was prepared in ethanol: mp 201-203°C
  • the oxalate salt was prepared in THF: mp 181-183 °C
  • the fumarate salt was prepared in ethanol: mp 203-205°C Elemental analysis for C 23 H 24 N 2 O » 0.5C 4 H 4 O 4 «0.25H 2 O Calc'd: C, 73.78; H,6.56; N, 6.88
  • the PCR cloning of the human 5-HT 1A receptor subtype from a human genomic library has been described previously Chanda et al., Mol. Pharmacol.. 43:516 (1993).
  • a stable Chinese hamster ovary cell line expressing the human 5-HT 1A receptor subtype (5-HT 1A .CHO cells) was employed throughout this study. Cells were maintained in DMEM supplemented with 10% fetal calf serum, non-essential amino acids and penicillin/ streptomycin.
  • Cells were grown to 95-100% confluency as a monolayer before membranes were harvested for binding studies. Cells were gently scraped from the culture plates, transferred to centrifuge tubes, and washed twice by centrifugation (2000 rpm for 10 min., 4°C) in buffer (50 mM Tris; pH 7.5). The resulting pellets were aliquoted and placed at -80°C. On the day of assay, the cells were thawed on ice, and resuspended in buffer. Studies were conducted using [ 3 H]8-OH-DPAT as the radioligand. The binding assay was performed in 96 well microtiter plates in a final total volume of 250 ⁇ L of buffer.
  • the [ 35 S]-GTP ⁇ S binding assay was similar to that disclosed by Lazareno and Birdsall, Br. J. Pharmacol.. 109: 1120, (1993). Briefly, 5-HT 1A cloned receptor membrane fragments (as used for 5-HT 1A receptor binding assays) were stored at -70 °C until needed. When needed, membranes were rapidly thawed, centrifuged at 40,000 x g for 10 minutes and resuspended at 4 °C for 10 minutes in assay buffer (25 mM HEPES, 3 mM MgCl 2 , 100 mM NaCI, 1 mM EDTA, 10 uM GDP, 500 mM DTT, pH 8.0).
  • assay buffer 25 mM HEPES, 3 mM MgCl 2 , 100 mM NaCI, 1 mM EDTA, 10 uM GDP, 500 mM DTT, pH 8.0.
  • the following assays were performed by incubating the cells with DMEM containing 25 mM HEPES, 5 mM theophylline and 10 ⁇ M pargyline for a period of 20 minutes at 37°C. Functional activity was assessed by treating the cells with forskolin (1 uM final concentration) followed immediately by test compound (6 concentrations) for an additional 10 min at 37°C. In separate experiments, 6 concentrations of antagonist were preincubated for 20 min prior to the addition of 10 nM 8-OH-DPAT and forskolin. The reaction was terminated by removal of the media and addition of 0.5 ml -42- ice cold assay buffer. Plates were stored at -20°C prior to assessment of cAMP formation by a cAMP SPA assay (Amersham).
  • the compounds of the present invention are active towards 5HT1 A receptors and generally elevate serotonin levels by inhibiting 5-HT transport. Accordingly, the present compounds should be useful in treating disorders related to defects in serotonin concentration.
  • the compounds of this invention may be administered orally or parenterally, neat or in combination with conventional pharmaceutical carriers.
  • Applicable solid carriers can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents or an encapsulating material.
  • the carrier is a finely divided solid which is in admixture with the finely divided active ingredient.
  • the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain up to 99% of the active ingredient. Any of the solid carriers known to those skilled in the art may be used with the compounds of this invention.
  • Particularly suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins.
  • Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups and elixirs of the compounds of this invention.
  • the compounds of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat.
  • the liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo- regulators.
  • liquid carriers for oral and parenteral administration include water (particularly containing additives as above, e.g., cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g., glycols) and their derivatives and oils (e.g., fractionated coconut oil and arachis oil).
  • the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate.
  • Sterile liquid carriers are used to prepare compositions for parenteral administration. - 44 -
  • Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously.
  • Compositions for oral administration may be either in liquid or solid composition form.
  • the pharmaceutical compositions containing the compounds of this invention are in unit dosage form, e.g., tablets or capsules.
  • the compositions may be sub-divided in unit doses containing appropriate quantities of the present compounds.
  • the unit dosage forms can be packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids.
  • the unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.
  • the therapeutically effective amount of the compounds of this invention that is administered and the dosage regimen depends on a variety of factors, including the weight, age, sex, and medical condition of the subject, the severity of the disease, the route and frequency of administration, and the specific compound employed, and thus may vary widely.
  • the pharmaceutical compositions may contain the compounds of this invention in the range of about 0.1 to about 2000 mg, preferably in the range of about 0.5 to about 500 mg and more preferably between about 1 and about 100 mg.
  • Projected daily dosages of active compound are about 0.01 to about 100 mg/kg body weight. The daily dose can be conveniently administered two to four times per day.

Abstract

Compounds useful for alleviating symptoms of depression (5-HT1A receptor active agents) are provided which have formula (I), wherein: R1 is hydrogen, lower alkyl or aryl; R2 is hydrogen, lower alkyl, phenyl or substituted phenyl; X and Y are each, independently, hydrogen, lower alkyl, lower alkoxy, or halogen, or together combined with the carbon atoms to which they are attached to complete a cyclopentyl, cyclohexyl, phenyl, pyrrolyl, pyranyl, pyridinyl, dihydrofuranyl, furanyl, dioxanyl, oxazolyl or isoxazolyl group; Z is hydrogen, halogen or lower alkoxy; with the proviso that when X, Y or Z represent lower alkoxy, they are not present at the ortho position; W is hydrogen, halogen, lower alkyl, cyano or a trifluoromethyl group; and n is 2-5; or pharmaceutically acceptable salts thereof.

Description

N-ARYLOXYETHYL-INDOLY-ALKYLAMINES FOR THE TREATMENT OF DEPRESSION (5-HT1A RECEPTOR ACTIVE AGENTS)
FIELD OF INVENTION
The present invention relates to compounds useful for the treatment of diseases affected by disorders of the serotonin-affected neurological systems. More specifically, the present invention is directed to aryloxyethyl-indoly-alkylamine derivatives useful for the treatment of such diseases.
10
BACKGROUND OF INVENTION
Pharmaceuticals which enhance neurotransmission of serotonin (5-HT) are useful for the treatment of many psychiatric disorders, including depression and anxiety. The first generation of non-selective serotonin-affecting compounds operated
15 through a variety of physiological means which caused them to possess numerous undesired side effects, such as dry mouth, blurred vision, and sedation due to multiple receptor activities. The more recently introduced compounds, i.e., the selective serotonin reuptake inhibitors (SSRIs), act predominately by inhibiting 5-HT, which is released at the synapses, from being actively removed from the synaptic cleft via a
20 presynaptic serotonin transport carrier. As SSRIs require several weeks before they exert their full therapeutic effect, this 5-HT blockade mechanism cannot fully account for their therapeutic activity. It is speculated that this two week induction which occurs before a full antidepressant effect is observed, is due to the involvement of the 5-HT1A autoreceptors which suppress the firing activity of the 5-HT neurons, causing a
25 dampening of the therapeutic effect. Studies suggest that after several weeks of SSRI administration, a desensitization of the 5-HT autoreceptors occurs allowing a full antidepressant effect in most patients, see Le Poul et al., Arch. Pharmacol.. 352: 141 (1995). Hence, it is believed that overriding this negative feedback by using 5HT1A antagonists would increase and accelerate the clinical antidepressant response. Recent
30 studies by Artigas et al., Trends Neurosci.. 19:378-383, (1996) suggest that a combination of 5-HT1A activity and inhibition of 5-HT uptake within a single molecular entity can achieve a more robust and fast-acting antidepressant effect.
The present invention relates to a new class of molecules which have the ability 35 to act concommitantly at the 5-HT1A autoreceptors and with the 5-HT transporter. Such compounds are therefore potentially useful for the treatment of anxiety or depression, as well as other serotonin disorders. U.S. Patent No. 3,371,098 discloses sec. and tert. indolylethylamines useful as sedatives, anticonvulsants and analegesics.
U.S. Patent No. 5,436,264 discloses N-aryloxyalkyl-tryptamine-like compounds of the following formula as alpha- 1-adrenergic receptor antagonists for the treatment of cardiovascular disorders. H
R3 R,
Figure imgf000004_0001
Figure imgf000004_0002
EP 0722 941 A2 discloses the preparation of a series of hetero-oxy alkanamines of the following formula for the treatment of depression and other disorders for which serotonin uptake inhibitors are normally used. x I
0(CH2)r -CHCH2(CH2)s-R
Figure imgf000004_0003
Japanese Patents 05255302 and 09040648 disclose the following compounds which are reported to be useful for the treatment of central nervous system-related diseases, such as anxiety and depression.
Rs
- ,.R R22 =\^e
OCH2CH2NHY 0-A-NR4-B
R3 <
R J7
Figure imgf000004_0004
Figure imgf000004_0005
- 3 -
SUMMARY OF INVENTION
The compounds of the present invention invention are aminomethyl benzoxezine indoles represented by Formula I:
Figure imgf000005_0001
CH2)n
H ^ N— (
Figure imgf000005_0002
wherein:
Rj is hydrogen, lower alkyl, or aryl;
R2 is hydrogen, lower alkyl, phenyl, or substituted phenyl;
X and Y are each, independently, hydrogen, lower alkyl, lower alkoxy, or halogen, or together combine with the carbon atoms to which they are attached to complete a cyclopentyl, cyclohexyl, phenyl, pyrrolyl, pyranyl, pyridinyl, dihydrofuranyl, furanyl, dioxanyl, oxazolyl, or isoxazolyl group;
Z is hydrogen, halogen, or lower alkoxy; with the proviso that when X, Y or Z represent lower alkoxy, they are not present at the ortho position; W is hydrogen, halogen, lower alkoxy, lower alkyl, cyano, or a trifluoromethyl group; and n is 2-5; or pharmaceutically acceptable salts thereof.
The present invention is further derived to pharmaceutical compounds containing such compounds, as well as methods for alleviating symptoms of depression comprising administering the present compounds to a patient in need thereof.
DETAILED DESCRIPTION OF THE INVENTION Preferably, the compounds of the present invention are those represented by
Formula I, wherein:
Rj is hydrogen, methyl or aryl;
R2 is hydrogen;
X and Y are each, independently, hydrogen, halogen or lower alkoxy, or together combine with the carbon atoms to which they are attached to complete a cyclopentyl, cyclohexyl, phenyl, pyridinyl, dioxanyl, oxazolyl, furanyl or dihydrofuranyl group; - 4 -
Z is hydrogen, halogen or lower alkoxy; with the proviso that when X, Y or Z are lower alkoxy they are not present at the ortho position; W is hydrogen or halogen; and n is 2-4; or pharmaceutically acceptable salts thereof.
Most preferably, the compounds of the present invention are selected from the following:
[3-(5-Fluoro-lH-indol-3-yl)-propyl]-[2-(lH-indol-4-yloxy)-ethyl]-amine; [2-(lH-Indol-4-yloxy)ethyl]-[3-(lH-indol-3-yl)-propyl]-amine;
[3-(lH-Indol-3-yl)-butyl]-[2-(lH-indol-4-yloxy)-ethyl]-amine;
[2-(2,3-Dihydro-benzo[l,4]dioxin-5-yloxy)-ethyl]-[2-(lH-indol-3-yl)-ethyl]-amine;
[2-(2,3-Dihydro-benzo[l,4]dioxin-5-yloxy)-ethyl]-[3-(5-fluoro-lH-indol-3-yl)- propyl] -amine; [2-(6-Fluorochroman-8-yloxy)-ethyl]-[2-( lH-indol-3-yl)-ethyl]-amine;
[2-(6-Fluorochroman-8-yloxy)-ethyl]-[3-(5-fluoro-lH-indol-3-yl)-proρyl]-amine;
[2-(6-Fluorochroman-8-yloxy)-ethyl]-[2-(5-fluoro-lH-indol-3-yl)-ethyl]-amine;
[2-(2,3-Dihydro-benzofuran-7-yloxy)-ethyl]-3-(5-fluoro-lH-indol-3-yl)-propyl]-amine;
[2-(Benzofuran-7-yloxy)-ethyl]-[3-(5-fluoro-lH-indol-3-yl)-propyl]-amine; [2-(5-Fluoro-2,3-dihydro-7-yloxy)-ethyl]-[2-(5-fluoro-lH-indol-3-yl)-ethyl]-amine;
[3-(5-Fluoro-lH-indol-3-yl)-propyl]-[2-(indan-4-yloxy)-ethyl]-amine;
[3-(5-Fluoro-lH-indol-3-yl)-propyl]-[2-(5,6,7,8-tetrahydro-naphthalen-l-yloxy)- ethyl]-amine;
[3-(lH-Indol-3-yl)-propyl]-[2-(naphthalen-l-yloxy)-ethyl]amine; [3-( lH-Indol-3yl)-proρyl]-(2-phenoxy-ethyl)-amine;
[3-(5-Fluoro-lH-indol-3yloxy)-propyl]-[2-(indan-5-yloxy)-ethyl]-amine;
[3-(lH-Indol-3-yl)-ρropyl]-[2-(quinolin-8-yloxy)-ethyl]-amine;
[3-(5-Fluoro-lH-indol-3-yl)-propyl]-[2-(2-methoxy-phenoxy)-2-phenyl-ethyl]-amine; and [3-(5-Fluoro-lH-indol-3-yl)-propyl]-[2-(2-methoxy-phenoxy)-propyl]amine;
As used herein, the terms "lower alkyl" and "lower alkoxy" are meant to include both straight and branched carbon chains containing 1 to 6 carbon atoms. The term
"halogen" is meant to include fluorine, chlorine, bromine, and iodine. The term
"substituted phenyl" is meant to include a phenyl moiety substituted with an alkyl, halogen, or alkoxy group. The term "aryl" is meant to include aromatic radicals containing 6-12 carbon atoms. The compounds of Formula I may advantageously be used in the form of the pharmaceutically acceptable acid addition salts thereof. Such salts, which may be prepared by methods well known to those skilled in the art, may be formed with both inorganic or organic acids, for example: fumaric, maleic, benzoic, ascorbic, pamoic, succinic, bismethylenesalicylic, methanesulfonic, ethanedisulfonic, acetic, oxalic, propionic, tartaric, salicyclic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzene-sulfonic, hydrochloric hydrobromic, sulfuric, cyclohexylsulfamic, phosphoric and nitric acids.
The compounds of the present invention may be prepared by any suitable method known to those skilled in the art. However, the present compounds may be advantageously prepared according to any one of Schemes 1 to 10 set forth below. In the Schemes, the intermediate compounds discussed hereinafter are identified in parenthesis. The compound produced in each of Schemes 1 to 10 is identified with reference to the appropriate, corresponding Example.
Scheme 1
Figure imgf000007_0001
LAH
Pd/C
Figure imgf000007_0002
Figure imgf000007_0003
OMe
N' H
Figure imgf000007_0004
Figure imgf000007_0005
Ex. 1 -6-
Scheme 2
Figure imgf000008_0001
Figure imgf000008_0002
(6) (7)
Figure imgf000008_0003
(8) 0)
OMθ
(7) Pd/C, H2
Figure imgf000008_0005
Figure imgf000008_0004
(3)
Figure imgf000008_0006
OMe
Figure imgf000008_0007
7-
Scheme 3
Figure imgf000009_0001
H
(11)
^~ NaN3 >
OHH KK22CC°033.,
Figure imgf000009_0003
OCH3 OCH3
(15)
Figure imgf000009_0008
Figure imgf000009_0004
Figure imgf000009_0006
Ex.3
Br
Figure imgf000009_0005
H
Figure imgf000009_0007
OCH
Figure imgf000009_0002
(12) Ex.4
Scheme 4
Figure imgf000009_0009
H
I N— (CH2)Fr-^ NH
\ -OHS ^^c /T\
1 (9 or 19) ^ =(
HN.
DIAD ^
(20) Ex.5 Scheme 5
Cl NaN *N3
4 PP .
Figure imgf000010_0002
O
Figure imgf000010_0003
Figure imgf000010_0001
O
(21) (22) (23)
NH, Br
Figure imgf000010_0005
O
Figure imgf000010_0007
Figure imgf000010_0004
O n
Figure imgf000010_0006
(24) Ex.6
"Cl
Figure imgf000010_0008
+
O
(22)
Figure imgf000010_0009
Scheme 6
PdC CI2CHOMe < _OH Br^c| <f Cl
NaN3
H2 TiCI4 K2C03
Figure imgf000011_0001
Figure imgf000011_0002
Figure imgf000011_0003
MEK
(25) (26) (27) (28)
Figure imgf000011_0005
Br
/ \
N3
PPh3 v< NH, O H
Figure imgf000011_0007
Figure imgf000011_0004
Figure imgf000011_0006
(29) (30) Ex.8
/(CH2 Cl (7 or 12) HN-
Figure imgf000011_0010
Figure imgf000011_0008
Figure imgf000011_0009
Ex.9
(28)
10
Scheme 7
CH3 CH3
BBrs HO— ^.Cl "Cl quinoline
PPh3, Pd/C, H2
Figure imgf000012_0002
Figure imgf000012_0001
Figure imgf000012_0003
DIAD
Figure imgf000012_0004
(31) (32) (33)
"Cl
Figure imgf000012_0005
(34)
Cl
Figure imgf000012_0006
Figure imgf000012_0007
(34) Ex.11
Figure imgf000012_0008
11
Scheme 8
Figure imgf000013_0001
Figure imgf000013_0002
Figure imgf000013_0003
12
Scheme 9
H H
Figure imgf000014_0002
N' H V NH
Figure imgf000014_0001
W /
Ex. 15
Scheme 10
OCH3
OH .OH
NaBH •cι U
^
Figure imgf000014_0004
PPh3,
Figure imgf000014_0007
DIAD
(49) (50)
Figure imgf000014_0008
Figure imgf000014_0003
Figure imgf000014_0005
Ex.16
OTs
Figure imgf000014_0006
OCH3 OCH3 C*H
(52) (53)
Figure imgf000014_0009
- 13 -
The present invention will now be illustrated by reference to the following specific, non-limiting examples.
INTERMEDIATE 2 [2-(2-Methoxy-phenoxy-ethyl]-benzyI-carbamic acid tert-butyl ester
To a solution of (2-hydroxy-ethyl)-benzyl-carbamic acid tert-butyl ester ( 3.2 g, 12.6 mmol) and 2-methoxy phenol (1.0 g, 8.4 mmol) containing triphenylphosphine (3.3 g, 12.6 mmol) in anhydrous tetrahydrofuran (40 ml) was slowly added diisopropyl azodicarboxylate (2.5 g, 12.6 mmol). The reaction was allowed to stir for 18 hours, then poured into methylene chloride (250 ml) and washed with IN sodium hydroxide (3 x 80 ml), dried over anhydrous magnesium sulfate, filtered and concentrated to a clear oil. The oil was dissolved in ether (70 ml) and hexanes were slowly added until the triphenylphosphine oxide precipitated. The solid was filtered and the solvent removed. The thick oil was then purified by column chromatography (15% ethyl aceate-hexanes) to afford 2.57 g (57.0%) of a clear oil: MS (El) 358 mJe (M+). Elemental analysis for C21H27NO4
Calc'd: C, 70.56; H, 7.61; N, 3.92 Found: C, 70.27; H, 7.58; N, 4.07
INTERMEDIATE 3 [2-(2-Methoxy-phenoxy)-ethyl]-benzyl-amine
To a solution of 2-(2-methoxy-phenoxy-ethyl]-benzyl-carbamic acid tert-butyl ester ( 18.0 g, 50.4 mmol) in methylene chloride (350 ml) was slowly added trifluoroacetic acid (60 ml). The reaction was stirred at room temperature for 12 hours, and then poured into 1 N sodium hydroxide (200 ml) and extracted with methylene chloride (3 x 150 ml). The combined organic layers were washed with 1 N sodium hydroxide (2 x 150 ml) followed by water (2 x 100 mL), then dried over anhydrous magnesium sulfate, filtered, and the solvent removed under vacuum. Chromatography (5% methanol-methylene choride) afforded 12.4 g (96 %) of a clear oil. Elemental analysis for C16H19NO2
Calculated: C, 74.19; H, 7.24; N, 5.54
Found: C, 73.91; H, 7.28; N, 5.44 - 14 -
The fumarate salt was prepared in ethanol: mp 121.5 -122°C: Elemental analysis for CI6H19NO2 »C4H4O4
Calc'd : C, 63.56; H, 6.27; N, 3.71
Found: C, 63.35; H, 6.16; N, 3.62
INTERMEDIATE 4 N-BenzyI-3-(lH-indoI-3-yl)-N-[2-(2-methoxy-phenoxy)- ethyl]-propion-amide (4a) To a solution of 3-indole propionic acid (4.1 g, 21.7 mmol) and l-(3-dimethyl- amino-propyl)-3-ethylcarbodiimide hydrochloride (4.4 g, 23 mmol) in methylene chloride (80 ml) was added a solution of 2-(2-Methoxy-phenoxy)-ethyl]-benzyl-amine (3 g, 11.6 mmol) in methylene chloride (20 ml) at 0 °C. After 2 hours, the reaction mixture was poured into water (200 ml) and extracted with methylene chloride (2 x 50 ml). The combined organic layers were washed with IN sodium hydroxide (50 ml), followed by water (2 x 50 ml). The organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent removed under vacuum. Chromatography (5% methanol-methylene chloride) provided 3.3 g (66.0%) of product as a white solid: mp 46.5-47.5°C. MS El m/e 428 (M+)
N-Benzyl-3-(lH-indol-3-yl)-N-[2-(2-methoxy-phenoxy)
-ethyl] -butyr-amide (4b)
Replacing 3-indole propionic acid with 3-indole butyric acid (1.8 g, 8.9 mmol) in (4a) above afforded N-benzyl-3-(lH-indol-3-yl)-N-[2-(2-methoxy-phenoxy)-ethyl] buty-amide (1.3 g; 78 %) as a white foam. MS FAB m/e AA (M + H)+ MS FAB m/e 465 (M + Na)+
INTERMEDIATE 5 Benzyl-[3-(lH-indoI-3-yl)-propyl]-[2-(2-methoxy- phenoxy)-ethyl]amine (5a) To a solution of N-benzyl-3-(lH-indol-3-yl)-N-[2-(2-mefhoxy-phenoxy)- ethyl]-propion-amide in tetrahydrofuran (50 mL) at room temperature was added lithium aluminum hydride (1.8 g). The reaction was heated to reflux for 12 hours then allowed to cool to room temperature. The reaction was qauenched with saturated ammonium chloride and the solid precipitates filtered through celite. The solvent was concentrated under vacuum and the product purified by chromatography (5% methanol- methylene chloride) to afford 2.0 g (86%) of product as a yellow oil. MS El m/e 414 (M+) - 15 -
Elemental analysis for C27H30N2O
Calc'd: C, 78.23; H, 7.30; N, 6.76
Found: C, 77.53; H, 6.95; N, 6.90
Benzyl-[4-(lH-indoI-3-yl)-butyl]-[2-(2-methoxy- phenoxy)-ethyI]-amine (5b)
Replacing N-benzyl-3-(lH-indol-3-yl)-N-[2-(2-methoxy-phenoxy)-ethyl]- propion-amide with N-benzyl-3-(lH-indol-3-yl)-N-[2-(2-methoxy-phenoxy)-ethyl]- butyl-amide (1.2 g, 2.7 mmol) in (5a) afforded N-benzyl-3-(lH-indol-3-yl)-N-[2-(2- methoxy-phenoxy)-ethyl]-butyl-amide (1.06 g, 91 %) as a white oil. MS El m/e 428
(M+)
INTERMEDIATE 7 5-Fluoro-indolyl-3-propylbromide A solution of 3-(5-fluoro-lH-indol-3-yl)-propan-l-ol (Intermediate 6) prepared in accordance with the procedures set forth in Demerson et al., J. Med. Chem.. 19:391- 395 (1976). (25.4 g, 0.13 mol), carbon tetrabromide (65.5 g, 0.2 mol) and triphenylphosphine (52 g, 0.2 mol) in methylene chloride (156 ml) was allowed to stir for 2 hours. The solvent was evaporated and the product chromatographed ( 30% ethyl acetate-hexanes) to afford 33.5 g (99 %) of product.
INTERMEDIATE 8 5-Fluoro-indolyl-3-propylazide
A solution of 5-fluoro-indolyl-3-propylbromide (10.67 g, 41 mmol) and sodium azide (3.9 g, 60 mmol) in anhydrous N,N-dimethylformamide (60 ml) was allowed to stir at 60°C for 18 hours. The mixture was poured into water (150 ml), extracted with methylene chloride (3 x 150 ml), washed with water (3 x 100 ml). The organic layer was dried over sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography (30% ethyl acetate-hexanes) afforded 8.10 g (89%) of product as a clear oil.
Elemental analysis for C11Η11FN3
Calc'd: C, 60.54; H, 5.08; N, 25.67
Found: C, 60.62; H, 5.08; N, 25.84 - 16 -
INTERMEDIATE 9 5-FIuoro-indolyl-3-propylamine
A solution of 5-fluoro-indolyl-3-propylazide (8 g, 0.037 mol) and 10% palladium on carbon in ethanol was hydrogenated at 50 psi for 16 hours. The catalyst was filtered and the solvent removed under vacuum. The celite was washed with methanol (300 ml) and the solvent was removed under vacuum. Chromatography
(15% methanol-methylene chloride plus ammonium hydroxide) afforded 4.33 g (61%) of product as a yellow solid: mp 82-84.5°C. Elemental analysis for CπH,3FN2
Calc'd: C, 68.73; H, 6.82; N, 14.57
Found: C, 68.82; H, 6.85; N, 14.49
INTERMEDIATE 10 [3-(5-Fluoro-lH-indol-3-yl)-propyl]-[2-(2-Methoxy-phenoxy) ethyl]-benzylamine
A solution of [2-(2-methoxy-phenoxy)-ethyl]-benzyl-amine (1.0 g, 3.9 mol), 3-
(5-fluoro-lH-indol-3-yl)-propylamine (1.4 g, 5.8 mmol) and triethylamine (0.79 g,
7.8 mmol) in dimethylsulfoxide (40 ml) was allowed to stir for 16 hours at 100°C. The reaction mixture was poured into water (100 ml) and extracted with methylene chloride (3 x 100 ml). The organic layer was washed with water (3 x 100 ml), dried over anhydrous sodium sulfate, filtered, and the solvent was removed under vacuum.
Chromatography (30% ethyl acetate-hexanes) afforded 0.94 g (58%) of product as a yellow oil. MS El m/e 432 (M+)
INTERMEDIATE 11 2-(5-Fluoro-lH-indol-3-yl)ethanol To a solution of 5-fluoro-indol-3-acetic acid (4.3 g, 0.022 mol) in anhydrous
THF (35 ml) was added LiAlH4 (1.0 M, 33 ml, 0.033 mol) at 0°C. The mixture was allowed to stir for 0.5 hours and, then quenched by saturated NH4C1 solution. The mixture was then filtered through celite. The filtrate was washed with IN NaOH (3 x
100 ml) and extracted with ethyl acetate (3 x 100 ml). The organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent was removed under vacuum.
Chromatography (10% methanol-methylene chloride) afforded 4.04 g (100%) of product as an off-white solid: mp 59-61°C.
Elemental analysis for C10H10FNO - 17 -
Calc'd: C, 67.03; H, 5.63; N, 7.82
Found: C, 66.71; H, 5.50; N, 7.74
INTERMEDIATE 12 3-(5-FIuoro-lH-indol-3-yI)-ethylbromide
To a solution of 2-(5-fluoro-lH-indol-3-yl)ethanol (4 g, 22.5 mmol) in methylene chloride (50 ml) was added carbon tetrabromide (11.2 g, 34 mmol), followed by triphenylphosphine (8.8 g, 33 mmol) at room temperature. The reaction mixture was allowed to stir at room temperature for 2.5 hours. The solvent was removed under vacuum. Chromatography (30% ethyl acetate-hexanes) afforded 5.91 g (98%) of product as an off -white solid: mp 58-59°C. Elemental analysis for C,0H9FBrN
Calc'd: C, 49.61; H, 3.75; N, 5.79
Found: C, 49.29; H, 3.73; N, 5.72
INTERMEDIATE 15 2-(5-Fluoro-2-methoxy-phenoxy)ethylchloride A solution of 5-fluoro-2-methoxy-phenol (4.34 g, 31 mmol) prepared in accordance with the procedures set forth in Mancini et al., Synth. Comm.. 19:2001- 2005 (1989), l-bromo-2-chloroethane (8.9 ml, 107 mmol) and potassium carbonate (14.8 g, 106 mmol) in 2-butanone (60 ml) was refluxed for 24 hours. The mixture was poured into water (150 ml), extracted with methylene chloride (3 x 150 ml) and washed with brine (3 x 100 ml). The organic layer was dried over sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography (20% ethyl acetate-hexanes) afforded 4.77 g (76%) of product as a clear oil. Elemental analysis for C9H]0FC1O2
Calc'd: C, 52.83; H, 4.93
Found: C, 52.79; H, 4.75
INTERMEDIATE 16
2-(5-Fluoro-2-methoxy-phenoxy)ethylazide
A solution of 2-(5-fluoro-2-methoxy-phenoxy)ethylchloride (3.97 g, 19 mmol) and sodium azide (2.6 g, 39 mmol) in anhydrous N,N-dimethylformide (60 ml) was allowed to stir at 60°C for 18 hours. The mixture was poured into water (150 ml), extracted with methylene chloride (3 x 150 ml), washed with water (3 x 100 ml). The organic layer was dried over sodium sulfate, filtered and the solvent was removed - 18 - under vacuum. Chromatography (20% ethyl acetate-hexanes) afforded 3.75 g (92%) of product as a clear oil.
Elemental analysis for C9H10FN3O2
Calc'd: C, 51.18; H, 4.77; N, 19.90 Found: C, 51.35; H, 4.71; N, 20.06
INTERMEDIATE 17 2-(5-Fluoro-2-methoxy-phenoxy)ethyIamine
A solution of 2-(5-fluoro-2-methoxy-phenoxy)ethylazide (3.97 g, 0.019 mol) and triphenylphosphine (5.95 g, 0.023 mol) in tetrahydrofuran (80 ml) and water (1.5 ml) was allowed to stir for 18 hours at room temperature. The solvent was removed under vacuum. Chromatography (ethyl acetate) removed triphenylphosphine and triphenylphosphine oxide and (25-50% methanol-ethyl acetate plus ammonium hydroxide) afforded 3.14 g (90%) of product as a clear oil. MS El m/e 185 (M+)
INTERMEDIATE 18
3-Indolyl-propionamide (18a)
A solution of 3-indolepropionic acid (15 g, 79 mmol), 1, r-carbonyldimidazole
(16.7 g, 100 mmol) in anhydrous tetrahydrofuran (150 ml) was allowed to stir for 1.5 hours at room temperature. Then NH3 was bubbled through the solution for 2.5 hours at room temperature. The solvent was removed under vacuum, and the residue was dissolved in ethyl acetate (500 ml). The organic solution was washed with water (3 x 150 ml ), dried over anhydrous sodium sulfate, filtered, and the solvent was removed under vacuum. The white solid was collected and dried under vacuum 10.42 g (96%); mp 124-125°C. MS El m/e 188 (M+)
3-Indolyl-butyramide (18b)
This compound was prepared in the manner described above for (18a), using 3-indolebutyric acid and 1, l'-carbonyldimidazole. A 96% yield was obtained as a off- white solid: mp 86-87°C.
INTERMEDIATE 19 3-Indolyl-propylamine (19a)
To a solution of 3-indolyl-propionamide (5 g, 24.7 mmol) in tetrahydrofuran anhydrous (150 ml) was added lithium aluminum hydride (1.0 M solution in tetrahydrofuran; 100 ml) slowly. The reaction mixture was refluxed for 3 hours, then - 19 - was quenched by adding water (4 ml), 15% sodium hydroxide (4 ml) and water (12 ml) at 0°C. The mixture was filtered through celite and concentrated under vacuum. Chromatography (10% methanol-methylene chloride plus ammonium hydroxde) afforded 4.0 g (86%) of product as a white solid: mp 58-60.5°C. MS El m/e \1A (M'+)
3-Indolyl-butylamine (19b) This compound was prepared in in the manner described above for (19a) using 3-indolyl-butyramide and lithium aluminum hydride. A 75% yield was obtained as a yellow solid: mp 51-53°C.
INTERMEDIATE 20
2-(lH-IndoI-4-yloxy)ethylchloride
To a solution of 4-hydroxyindole (4 g, 30 mmol), 2-chloroethanol (4.83 g, 60 mmol), triphenylphosphine (15.7 g, 60 mmol) in anhydrous tetrahydroufuran (40 ml) was slowly added diisopropyl azodicarboxylate (12. Ig, 60 mmol). The reaction was allowed to stir for 2.5 hours at room temperature, then poured into methylene chloride
(250 ml), washed with water (3 x 100 ml) and dried over anhydrous sodium sulfate.
This material was filtered and the solvent was removed under vacuum. Chromatography (20% hexanes-ethyl acetate) to remove triphenylphosphine, (20% methylene chloride-hexanes) afforded 2.94 g (50%) of product as a white solid: mp 69.5-72°C.
INTERMEDIATE 21 5-Hydroxy-(2,3)-dihydrobenzo[l,4]dioxine Pyrogallol (5 g, 0.04 mol) was dissolved in 2-butanone (600 ml) to which potassium carbonate (1.82 g, 0.013 mol) was added. The mixture was stirred at reflux while 1,2-dibromoethane (2.48 g, 1. 14 ml, 0.013 mol) was slowly added dropwise. The reaction was allowed to stir overnight and then cooled to room temperature. The mixture was poured into water (100 ml) and extracted with methylene chloride (200 ml). The organic layer was dried over anhydrous sodium sulfate, filtered, and the solvent was removed under vacuum. Chromatography (5% methanol-methylene chloride) afforded 2.74 g (45%) of product as a clear oil. MS El m/e 152 (M+) - 20 -
INTERMEDIATE 22 5-(2-ChIoroethoxy)-(2,3)-dihydrobenzo[l,4]dioxane
To solution of 5-hydroxybenzodioxane (1.0 g, 6.5 mmol) and 2-chloroethanol (0.79 g, 9.9 mmol), triphenylphosphine (2.6 g, 9.9 mmol) in tetrahydrofuran (50 ml) was slowly added diisopropyl azidodicarbimide (DIAD) (2.0 g, 9.8 mmol). After 2 hours, another 1.5 eq of triphenylphosphine, DIAD, and 2-chloroethanol was added thereto and the mixture stirred for another 2 hours. The reaction mixture was poured into water (100 ml), and extracted with methylene chloride (100 ml). The organic layer was separated and dried over anhydrous magnesium sulfate. This material was filtered, and the solvent removed under vacuum. Chromatography (20% ethyl acetate-hexanes) afforded 1.7 g (76%) of product as a white solid: mp 70.5-72.5°C. Elemental analysis for C10H,,C1O3
Cal'd C, 55.96; H, 5.17
Found: C, 55.57; H, 5.20
INTERMEDIATE 23 2-(2,3-Dihydrobenzo[l,4]dioxin-5-yloxy)ethylazide A solution of 5-(2-chloroethoxy)-(2,3)-dihydrobenzo[l,4]dioxane (4.6 g, 0.02 mol) and sodium azide (2.78 g, 0.043 mol) in anhydrous N,N-dimethyl-formamide (100 ml) was allowed to stir for 18 hours at 60°C. The mixture was poured into water (200 ml), extracted with methylene chloride (3 x 100 ml). The organic layer was washed with water (3 x 150 ml), dried over anhydrous sodium sulfate, filtered, and the solvent removed under vacuum. Chromatography (20% ethyl acetate-hexanes) afforded 3.43 g (72%) of product as a clear oil. MS FAB m/e 221 (M+)
INTERMEDIATE 24 2-(2,3-Dihydrobenzo[l,4]dioxin-5-yloxy)ethylamine A solution of 2-(2,3-dihydrobenzo[l,4]dioxin-5-yloxy)ethylazide (3.43 g, 0.016 mol) and triphenylphosphine (6.3 g, 0.023 mol) in tetrahydrofuran (50 ml) and water (2 ml) was allowed to stir for 18 hours at room temperature. The solvent was removed under vacuum. Chromatography (30% methanol-methylene chloride plus ammonium hydroxide) afford 1.93 g (62%) of product as a yellow oil. MS FAB m/e 196 (M + H)+ - 21 -
INTERMEDIATE 25 6-Fluorochroman
A mixture of 6-fluoro-4-chromanone (2 g, 12 mmol) and 10% palladium on carbon (1 g) in concentrated hydrochloric acid (20 ml) and ethanol (30 ml) was hydrogenated for 20 hours. The catalyst was filtered and the solvent removed under vacuum. The residue was dissolved in ethyl acetate (100 ml), washed with IN NaOH (6 x 200 ml) and water (3 x 150 ml), dried over anhydrous sodium sulfate, filtered and the solvent was removed under vacuum. Chromatagraphy (20% ethyl acetate-hexanes) afforded 1.41 g (77%) of product as a clear oil. MS El m/e 152 (M+)
INTERMEDIATE 26 6-Fluorochroman-8-carbaldehyde To a solution of 6-fluorochroman (0.7 g, 4.6 mmol) in anhydrous methylene chloride (20 ml) was added TiCl4 (1.57 g, 8.3 mmol) and α,α'-dichloromethyl methyl ether (0.53 g, 4.6 mmol) slowly at 0°C. The reaction was allowed to reach room temperature slowly and stirred for 16 hours. The reaction mixture was poured into ice- water, extracted with methylene chloride (3 x 100 ml), washed with saturated sodium carbonate (5 x 150 ml) and brine (3 x 100ml). The organic layer was dried over anhydrous solium sulfate, filtered, and the solvent was removed under vacuum. The crude solid was collected and dried under the vacuum to afford 0.75 g (90%) of product as a yellow solid: mp 55-57°C. Elemental analysis for C10H9FO2
Calc'd: C, 66.66; H, 5.04
Found: C, 66.64; H, 4.78
INTERMEDIATE 27
6-Fluoro-8-hydroxychroman
To a solution of 6-fluorochroman-8-carbaldehyde (8.6 g, 48 mmol), 3-t-butyl-
4-hydroxy-5-methylphenyl sulfide (100 mg) in anhydrous methylene chloride (60 ml) at 0°C was added 3-chloroperoxybenzoic acid (mCPBA) (12.4 g, 70 mmol) portionwise. The reaction mixture was allowed to reflux for 16 hours. The excess mCBPA was destroyed by adding 10% sodium sulfite. The benzoic acid was filtered and the filtrate was extracted with methylene chloride (3 x 150 ml) and washed with water (3 x 150 ml). The organic layer was dried over anhydrous sodium sulfate and filtered. The solvent was removed under vacuum and the crude product (10.2 g, 52 mmol) was dissolved in ethanol-water (200 ml, 1: 1). To the above solution, sodium - 22 - hydroxide (6.2 g, 160 mmol) was added at 0°C. After 30 minutes, the ice bath was removed, and the reaction mixture was allowed to stir for 3 hours at room temperature. Ethanol was then evaporated. The residue was neutralized with concentrated hydrochloric acid, extracted with methylene chloride (3 x 150 ml), washed with saturated sodium bicarbonate (2 x 100 ml) and brine (2 x 100 ml). The organic layer was dried over sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography (25% ethyl acetate-hexanes) afforded 6.9 g (79%) of product as a white solid: mp 62-63 °C. Elemental analysis for C9H9FO2 Calc'd: C, 64.28; H, 5.39
Found: C, 64.31; H, 5.27
INTERMEDIATE 28 2-(6-Fluorochroman-8-yloxy)ethylchloride A solution of 6-fluorochroman-8-carbaldehyde (5.5 g, 33 mmol), l-bromo-2- chloroethane (16.4 g, 114 mmol) and K2CO3 (16 g, 114 mmol) in 2-butanone (60 ml) was refluxed for 24 hours. The mixture was poured into water (150 ml), extracted with methylene chloride (3 x 150 ml) and washed with brine (3 x 100 ml). The organic layer was dried over sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography (20% ethyl acetate-hexanes) afforded 5.74 g of product as a white solid: mp 89-90°C. Elemental analysis for CπH12FClO2
Calc'd: C, 57.28; H, 5.24
Found: C, 57.15; H, 5.69
INTERMEDIATE 29 2-(6-Fluorochroman-8-yloxy)ethylazide A solution of 2-(6-fluorochroman-8-yloxy)ethylchloride (4.13 g, 0.018 mol) and sodium azide (2.33 g, 0.036 mol) in anhydrous DMF (60 ml) was allowed to stir at 60°C for 18 hours. The mixture was poured into water (150 ml), extracted with methylene chloride (3 x 150 ml) and washed with water (3 x 100 ml). The organic layer was dried over sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography (20% ethyl acetate-hexanes) afforded 4.12 g (97%) of product as a clear oil. Elemental analysis for CnH12FN3O2
Calc'd: C, 55.69; H, 5.10; N, 17.71
Found: C, 55.44; H, 4.97; N, 17.88 23
INTERMEDIATE 30 2-(6-Fluorochroman-8-yloxy)ethylamine
A solution of 2-(6-fluorochroman-8-yloxy)ethylazide (4.12 g, 0.017 mol) and triphenylphosphine (6.83 g, 0.026 mol) in tetrahydrofuran (80 ml) and water (1.5 ml) was allowed to stir for 18 hours at room temperature. The solvent was removed under vacuum. Chromatography (ethyl acetate) removed triphenylphosphine and triphenylphosphine oxide and (40% methanol-methylene chloride plus ammonium hydroxide) afforded 3.45 g (94%) of product as a white solid: mp 68-70°C. Elemental analysis for CπH]4FNO2
Calc'd: C, 62.55; H,6.68; N, 6.63
Found: C.62.18; H, 6.54; N,6.63
INTERMEDIATE 31 7-Methoxybezofuran
A solution of 7-methyoxy-2-benzofurancarboxylic acid (5 g, 0.026 mol), copper (0.2 g) in quinoline (30 ml) was heated under reflux for 2 hours. The mixture was filtrated through the celite. The celite was washed with ethyl acetate. The solvent was removed under vacuum. Chromatography (25% ethyl acetate-hexanes) afforded 2.45 g (64%) of product as a yellow oil. MS El m/e 148 (M+)
INTERMEDIATE 32 7-Hydroxybezofuran
7-Methoxybenzofuran (1 g, 6.7 mmol) was dissolved in anhydrous methylene chloride (25 ml) in a 100 ml round-bottom flask. The flask was placed in an acetone- ice bath at -78°C. The flask was fitted with a air-condenser. A solution of boron tribromide in methylene chloride (1 M, 10 ml) was added carefully to the stirred solution through the condenser. The reaction was kept at -78°C for 6 hours and then was allowed to stir at room temperature overnight. The reaction was quenched by adding water (20 ml) and diluted with ethyl ether. The solvent was removed under vacuum. Chromatography (25% ethyl acetate-hexanes) afforded 0.47 g (52%) of product as a light-brown oil. MS El m/e 134 (M+)
INTERMEDIATE 33 2-(Benzofuran-7-yloxy)-ethylchloride
To a solution of 7-hydroxybenzofuran (0.47 g, 3.5 mmol), triphenylphosphine (2.3 g, 8.7 mmol) and 2-chloroethanol (0.7 g, 8.7 mmol) in tetrahydrofuran ((50 ml) - 24 - was slowly added diisopropyl azodicarboxylate (1.8 g, 8.7 mmol). The reaction was stirred at room temperature for 3 hours. THF was removed under vacuum. Chromatography (25 % ethyl acetate-hexanes) afforded 0.58 g (84%) of product as a yellow oil. MS El m/e 196 (M+)
INTERMEDIATE 34 2-(2,3-Dihydrobenzofuran-7-yloxy)ethylchloride A solution of 2-(benzofuran-7-yloxy)-ethylchloride (0.64 g) and 10% palladium on carbon in acetic acid (20 ml) was hydrogenated under 40 psi for 20 hours. The catalyst was filtered off and the solvent removed under vacuum. Chromatography (20% ethyl acetate-hexanes) afforded 0.39 g (60%) of product as a white solid: mp 49- 52°C. MS El m/e 198 (M+)
INTERMEDIATE 35 2-(4-Fluorophenoxy)-acetaIdehyde diethyl acetal
To a suspension of NaOH (5.4 g, 0.134 mol) in anhydrous DMF (100 ml) was added 4-fluorophenol (10 g, 0.089 mol) at 0°C. After H2 evolution had ceased, bromo- acetaldehyde diethyl acetal (16 ml, 0.11 mol) was added. The reaction was heated at 160-170°C for 18 hours. The mixture was poured into ice-water, extracted with ethyl acetate (3 x 150 ml), washed with IN NaOH (3 x 100 ml) and brine (3 x 100 ml). The organic layer was dried over anhydrous sodium sulfate and filtered. The solvent was removed under vacuum. Chromatography (25% ethyl acetate-hexanes) afforded 16.36 g (80%) of product as a clear oil. MS El m/e 228 (M+)
INTERMEDIATE 36
5-Fluorobenzofuran
To a mixture of benzene (200 ml) containing polyphosphoric acid (7.9 g, 0.035 mol) was added 2-(4-fluoro-phenoxy)-acetaldehyde diethyl acetal (8 g, 0.035 mol). The mixture was stirred vigorously while being heated to reflux for 2.5 hours. The reaction mixture was cooled to room temperature and decanted from the polyphosphoric acid. The solvent was removed under vacuum. Chromatography (5% ethyl acetate- hexanes) afforded 3.4 g (45%) of product as a clear oil.
INTERMEDIATE 37 5-Fluoro-2,3-dihydrobenzofuran
A solution of 5-fluorobenzofuran and 10% palladium on carbon in acetic acid (25 ml) was hydrogenated under 50 psi for 12 hours. The catalyst was filtered through - 25 - celite, and the celite was washed with methylene chloride (200 ml). The organic layer was washed with IN NaOH (3 x 100 ml), brine (3 x 100 ml) and dried over anhydrous sodium sulfate. The solvent was removed under vacuum to afforded 2.59 g (85%) of product as a clear oil.
INTERMEDIATE 38 5-Fluoro-2,3-dihydrobenzofuran-7-carbaldehyde To a solution of 5-fluoro-2,3-dihydrobenzofuran (7 g, 0.051 mol) in anhydrous methylene chloride (40 ml) was added TiCl4 (9.5 ml, 0.087 mol), followed by α,α'- dichloromethyl methyl ether (4.6 ml, 0.051 mol) at 0°C. The reaction was allowed to reach room temperature slowly and stirred overnight. The reaction mixture was poured into ice- water slowly, extracted with methylene chloride (3 x 100 ml) and washed with saturated sodium carbonate (5 x 100 ml), and brine (3 x 100 ml). The organic layer was dried over anhydrous sodium sulfate and filtered. Chromatography (25% ethyl acetate-hexanes) afforded 3.29 g (39%) of product as a white solid: mp 103-104°C. Elemental analysis for C9H7FO2
Calc'd: C, 65.06; H, 4.75
Found: C, 65.01; H, 4.03
INTERMEDIATE 39
5-Fluoro-7-hydroxy-2,3-dihydro-benzofuran
To a solution of 5-fluoro-2,3-dihydrobenzofuran-7-carbaldehyde (3.29 g, 20 mmol), 3-t-butyl-4-hydroxy-5-methylphenyl sulfide (100 mg) in anhydrous methylene chloride (40 ml) at 0°C was added 3-chloroperoxybenzoic acid (mCPBA) (8.5 g, 30 mmol) portionwise. The reaction mixture was refluxed for 16 hours. The excess mCBPA was destroyed by adding 10% sodium sulfite. The benzoic acid was filtered off and the filtrate was extracted with methylene chloride (3 x 100 ml) and washed with water (3 x 100 ml). The organic layer was dried over anhydrous sodium sulfate and filtered. The solvent was removed under vacuum and crude product was dissolved in ethanol- water (100 ml, 1:1). To the above solution, sodium hydroxide (2.11 g, 53 mmol) was added at 0°C. After 30 minutes, the ice bath was removed, and the reaction mixture was allowed to stir for 3 hours at room temperature. Ethanol was evaporated and the residue was neutralized with concentrated hydrochloric acid. This mixture was extracted with methylene chloride (3 x 100 ml) and washed with saturated sodium bicarbonate (2 x 100 ml) and brine (2 x 100 ml). The organic layer was dried over sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography - 26 -
(30% ethyl acetate-hexanes) afforded 1.62 g (50%) of product as a white solid: mp
102.5-103.5°C.
Elemental analysis for C8H7FO2
Calc'd: C, 62.34; H, 4.58 Found: C, 62.19; H, 4.59
INTERMEDIATE 40 2-(5-Fluoro-2,3-dihydro-benzofuran-7-yloxy)ethylchloride
A solution of 5-fluoro-7-hydroxy-2,3-dihydro-benzofuran (1.6 g, 10 mmol), 1- bromo-2-chloroethane (7.8 g, 55 mmol) and K2CO3 (2.2 g, 16 mmol) in 2-butanone (40 ml) was refluxed for 24 hours. The mixture was poured into water (150 ml), extracted with methylene chloride (3 x 150 ml) and washed with brine (3 x 100 ml). The organic layer was dried over anhydrous sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography (25% ethyl acetate-hexanes) afforded 2.10 g of product as a white solid: mp 72.5-74.5°C. Elemental analysis for C10H10FC1O2
Calc'd: C, 55.44; H, 4.65
Found: C, 55.37; H, 4.58
INTERMEDIATE 41
2-(5-FIuoro-2,3-dihydrobenzofuran-7-yloxy)ethylazide
A solution of 2-(5-fluoro-2,3-dihydro-benzofuran-7-yloxy)ethylchloride (2.05 g, 9.4 mmol) and sodium azide (1.23 g, 19 mol) in anhydrous DMF (30 ml) was allowed to stir at 60°C for 24 hours. The mixture was poured into water (100 ml), extracted with methylene chloride (3 x 150 ml), washed with water (3 x 100 ml). The organic layer was dried over sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography (20% ethyl acetate-hexanes) afforded 2.0 g (95%) of product as a clear oil. MS ESI m/e 241 [M + 1]+
INTERMEDIATE 42
2-(5-Fluoro-2,3-dihydrofuran-7-yloxy)ethylamine
A solution of 2-(5-fluoro-2,3-dihydrobenzofuran-7-yloxy)ethylazide (1.98 g, 89 mmol) and triphenylphosphine (2.8 g, 10.6 mmol) in tetrahydrofuran (50 ml) and water (1.5 ml) was allowed to stir for 18 hours at room temperature. The solvent was removed under vacuum. Chromatography (ethyl acetate) removed triphenylphosphine and triphenylphosphine oxide and (40% methanol-methylene chloride plus ammonium hydroxide) afforded 2.0 g (100%) of product as a clear oil. MS ESI m/e 198 [M + 1]+ 27
INTERMEDIATE 44 4-Indanol
A solution of 1 g of 2-(5-fluoro-2,3-dihydrofuran-7-yloxy)ethylamine (Intermediate 43) (Intermediate 44), prepared in the manner described by Ross et al., Am. Chem. Soc. 110:6471-6480 (1988) and 10% palladium on carbon in acetic acid (50 ml), was hydrogenated for 36 hours. The catalyst was filtered off through celite. The celite was washed with methylene chloride. The organic layer was washed with saturated sodium carbonate (3 x 150 ml), brine (3 x 150 ml) and dried over sodium sulfate. The solvent was removed under vacuum. Chromatography (30% ethyl acetate- hexanes) afforded 0.78 g (86%) of product as a clear oil. MS El m/e 134 (M+)
INTERMEDIATE 45
2-(Indan-4-yloxy)-ethylchloride (45a) To a solution of 4-indanol (0.75 g, 5.6 mmol), triphenylphosphine (4.4 g, 16.8 mmol), 2-chloroethanol (0.7 g, 8.7 mmol) in tetrahydrofuran (50 ml) was slowly added diisopropyl azodicarboxylate (1.8 g, 8.7 mmol). The reaction was stirred at room temperature for 3 hours and the solvent was removed under vacuum. Chromatography
(25 % ethyl acetate-hexanes) afforded 0.58 g (84%) of product as a yellow oil. MS El m/e 196 (M+)
2-(5,6,7,8-Tetrahydronapthalen-l-yloxy)-ethylchloride (45b)
This compound was prepared in the manner described for 45(a) above by replacing 4-indanol with 5,6,7,8-tetrahydro-l-naphthol (4 g, 0.027 mol) ) in 46% yield (2.57 g) as a clear oil.
Elemental analysis for CI2HI5ClO
Calc'd: C, 68.41; H, 7.17
Found: C, 68.37; H, 7.25
2-(Napthalen-l-yloxy)-ethyIchloride (45c)
This compound was prepared in the manner described for 45(a) above by replacing 4-indanol with 1-naphthol (5 g, 0.035 mol) ) in 82% yield (6.34 g) as a clear oil.
Elemental analysis for C12HπClO Calc'd: C, 69.74; H, 5.37
Found: C, 69.64; H, 5.30 - 28 -
2-Phenoxy-ethylchloride (45d) This compound was prepared in the manner described above for 45(a) by replacing 4-indanol with phenol (5 g, 0.053 mol) ) in 12% yield (1.03 g) as a clear oil. MS El m/e 156 (M+)
INTERMEDIATE 46 2-(Indan-5-yloxy)-ethylchloride A solution of 5-indanol (5 g, 0.037 mol), l-bromo-2-chloroethanol (8.02 g, 0.056 mol) and potassium carbonate (7.7 g, 0.056 mol) in 2-butanone (40 ml) was refluxed for 18 hours. The mixture was poured into water (100 ml), extracted with methylene chloride (3 x 150 ml) and washed with water (3 x 100 ml). The organic layer was dried over anhydrous sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography (20% ethyl acetate-hexanes) afforded 3.2 g (43%) of product as a white solid: mp 45-46°C. Elemental analysis for C, ,H13ClO
Calc'd: C, 67.18; H, 6.66
Found: C, 67.03; H, 6.57
INTERMEDIATE 47 [3-(lH-IndoI-3-yl)-propyl]-(2-hydroxyethyl)amine
To a solution of 3-(lH-indol-3-yl)-propyl-amine (3.5 g, 18.6 mmol), 2-chloro- thanol (1 g, 12.4 mmol) in anhydrous dimethylsulfoxide (20 ml) was allowed to stir at 80°C for 12 hours. The mixture was poured into water (100 ml), extracted with methylene chloride (3 x 150 ml) and washed with water (3 x 100 ml). The organic layer was dried over anhydrous sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography (15% methanol-methylene chloride) afforded 1.04 g (38%) of product as a yellow oil. MS El m/e 218 (M+)
INTERMEDIATE 48 (2-Hydroxy-ethyl)-[3-(lH-indol-3-yl)-propyl]-carbamic acid-tert-butyl ester
A solution [3-(lH-indol-3-yl)-propyl]-(2-hydroxyethyl)amine (1.05 g, 4.5 mmol), di-tert-dicarbonate (5 g, 24 mmol) in anhydrous tetrahydrofuran (20 ml) was heated at 80°C for 2 hours. The mixture was poured into water (100 ml), extracted with methylene chloride (3 x 150 ml) and washed with water (3 x 100 ml). The organic layer was dried over anhydrous sodium sulfate, filtered and the solvent was removed - 29 - under vacuum. Chromatography (5% methanol-methylene chloride) afforded 0.86 g (56%) of product as a yellow oil. MS El m/e 318 (M+)
INTERMEDIATE 49 2-Chloro-l-phenylethanoI
A solution of 2-chloroacetophenone (5 g, 0.032 mol), sodium borohydride (6.1 g, 0.16 mol) in tetrahydrofuran (30 ml) was allowed to stir at 60°C for 18 hours. The reaction was quenched by water (200 ml) and stirred for another 2 hours. The mixture was extracted with methylene chloride (3 x 100 ml) and washed with water (3 x 150 ml). The organic layer was dried over sodium sulfate and filtered. The solvent was removed under vacuum and afforded 5.07 g(100%) of product as a clear oil. MS El m/e 156 (M+)
INTERMEDIATE 50 2-(2-Methoxy-phenoxy)-2-phenyl-ethylchloride
To a solution of guaiacol (2 g, 8.1 mmol), triphenylphosphine (6.4 g, 24 mmol), and 2-chloro-l-phenylethanol (3.78 g, 24 mmol) in tetrahydrofuran (50 ml) was slowly added diisopropyl azodicarboxylate (4..8 g, 24 mmol). The reaction was stirred at room temperature for 2 hours. Tetrahydrofuran was removed under vacuum. Chromatography (20 % ethyl acetate-hexanes) afforded 3.30 g (78%) of product as a clear oil. MS El m/e 262 (M+)
INTERMEDIATE 51 5-Fluoro-3-(3-p-toluenesulfonyloxypropyl)indole To a stirred solution of 3-(5-fluoro-lH-indol-3-yl)-propan-l-ol (2.90 g, 15.0 mmol) in pyridine (15.0 mL) was added p-toluenesulfonyl chloride (7.1 g, 37.5 mmol) at room temperature. After stirring for 30 minutes at room temperature, the reaction mixture was poured to 200 mL of ice water. The aqueous was extracted with ethyl acetate and the combined organic extracts were washed with IN HC1 and brine. The resulting material was dried over anhydrous sodium sulfate, filtered, and the solvent was concentrated under vacuum. The crude product was purified by silica gel column chromatography (ethyl acetate/hexane, 3/7) to give 4.1 g (79 %) of the tide compound as a solid: mp 74 °C (Lit. mp 99 °C; EP 464604 A2). - 30 -
INTERMEDIATE 52 2-(2-Methoxy-phenoxy)propionitrile
To a solution of guaiacol (5 g, 0.04 mol) in anhydrous N,N-dimethylformide (20 ml) was added sodium hydride (1.16 g, 0.048 mol). The mixture was allowed to stir at room temperature for 0.5 hours, followed by the addition of 2-bromopropionitrile (8.09 g, 0.06 mol). The mixture was allowed to stir for 4 hours at room temperature and quenched with water (20 ml). The mixture was extracted with methylene chloride (3 x 100 ml), washed with water (3 x 100 ml) and the organic layer was dried over anhydrous sodium sulfate and filtered. The solvent was removed under vacuum. Chromatography (20% ethyl acetate-hexanes) afforded 3.91 g (55%) of product as a clear oil. MS El m/e 111 (M+)
INTERMEDIATE 53 2-(2-Methoxy-phenoxy)propylamine To a solution of 2-(2-methoxy-phenoxy)-propionitrile (3.91 g, 0.022 mol) in anhydrous ethyl ether (30 ml) was added lithium aluminum hydride (1.0 M, 44 ml, 0.044 mol). The mixture was heated at 65°C for 18 hours and the reaction was quenched with water (3 ml), 15% NaOH (3 ml) and water (9 ml). The resulting material was filtered through celite. The celite was washed with methanol (200 ml), and the solvent was removed under vacuum. Chromatography (10% methanol- methylene chloride) afforded 0.26 g (7%) of product as yellow oil. MS El m/e 181 (M+)
EXAMPLE 1 [3-(lH-Indol-3-yl)-propyl]-[2-(2-methoxy-phenoxy)-ethyl]-amine
A mixture of benzyl-[3-(lH-indol-3-yl)-propyl]-[2-(2-methoxy-phenoxy)- ethyl]amine (2 g, 4.7 mmol) and 5% palladium on carbon in ethanol was hydrogenated for 20 hours. The catalyst was filtered off and the solvent removed under vacuum. Chromato-graphy (ethyl acetate-hexanes-methanol-ammonia hydroxide: 4/4/1/1) affored 0.79 g (52 %) of product as a white solid: mp 101-102°C. The fumarate salt was prepared in ethanol: mp 130-130.5°C. Elemental analysis for C20H24N2O2»C4H4O4
Calc'd: C, 64.78; H, 6.46; N, 6.29
Found: C, 64.76; H, 6.23; N, 6.21 - 31 -
[4-(lH-Indol-3-yl)-butyl]-[2-(2-methoxy-phenoxy)-ethyl] -amine
Hydrogenation of benzyl-[4-(lH-indol-3-yl)-butyl]-[2-(2-methoxy-phenoxy)- ethyl]- amine afforded 0.79 g (100 %) of product as a clear oil. The oxalate salt was prepared from isopropanol: mp 167-168 °C. Elemental analysis for C20H24N2O2 »C4H4O4
Calc'd: C, 64.47; H, 6.59; N, 6.54
Found: C, 64.44; H, 6.52; N, 6.46
EXAMPLE 2 [3-(5-Fluoro-lH-indol-3-yI)-propyl]-[2-(2-Methoxy-phenoxy)ethyI]- amine
A mixture of [3-(5-fluoro-lH-indol-3-yl)-propyl]-[2-(2-methoxy-phenoxy) ethyl] -benzylamine (0.94 g, 2.2 mol) and 10% palladium on carbon (250 mg) in ethanol was hydrogenated for 20 hours. The catalyst was filtered off and the solvent was removed under vacuum. Chromatography (10% methanol-methylene chloride) afforded 0.63 g (85%) of product as an off-white solid: mp 125-126°C. The oxalate salt was prepared in isopropanol: mp 146-149°C. Elemental analysis for C20H23FN2O2 »C2H2O4»0.5H2O Calc'd : C, 59.85; H, 5.94; N, 6.35 Found: C, 60.13; H, 5.67; N, 6.10
EXAMPLE 3 [3-(5-Fluoro-lH-indol-3-yl)propyI]-[2-(5-fluoro-2-methoxy-phenoxy)- ethyl]-amine A solution of 2-(5-fluoro-2-methoxy-phenoxy)ethylchloride (0.3 g, 1.5 mmol),
3-(5-fluoro-lH-indol-3-yl)propylamine (0.56 g, 2.9 mmol) in dimethylsulfoxide (20 ml) was allowed to stir for 12 h at 90°C. The reaction mixture was poured into water (100 ml) and extracted with methylene chloride (3 x 100 ml). The organic layer was washed with water (3 x 150 ml), dried over anhydrous sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography (10% methanol-methylene chloride) afforded 0.39 g (77%) of product as a white solid: mp 119-122°C. The oxalate salt was prepared in ethanol: mp 175-177°C Elemental analysis for C20H22F2N2O2 »C2H2O4
Calc'd: C, 58.66; H, 5.57; N, 6.22 Found: C, 58.29; H, 5.25; N, 6.07 - 32 -
[2-(5-FIuoro-lH-indol-3-yI)ethyl]-[2-(5-fluoro-2-methoxy- phenoxy)-ethyl]-amine (3b)
A solution of 2-(5-fluoro-2-methoxy-phenoxy)ethylamine (0.51 g, 2.8 mmol),
2-(5-fluoro-lH-indol-3-yl)ethylchloride (0.44 g, 1.8 mmol) and triethylamine (0.29 g, 3 mmol) in dimethylsulfoxide (20 ml) was allowed to stir for 8 hours at 90°C. The reaction mixture was poured into water (100 ml) and extracted with methylene chloride
(3 x 100 ml). The organic layer was washed with water (3 x 150 ml), dried over anhydrous sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography (5% methanol-methylene chloride) afforded 0.27 g (43%) of product as a brown oil.
The oxalate salt was prepared in ethanol: mp 185-188°C Elemental analysis for C19H20F2N2O2 »C2H2O4
Calc'd: C, 57.80; H, 5.08; N, 6.42
Found: C, 57.53; H, 4.95; N, 6.36
EXAMPLE 4 [2-(5-Fluoro-lH-indol-3-yl)ethyl]-[2-(5-fluoro-2-methoxy-phenoxy)- ethyl]-amine
A solution of 2-(5-fluoro-2-methoxy-phenoxy)ethylamine (0.41 g, 2.2 mmol), 3-(2-bromoethyl)indole (0.25 g, 1.1 mmol) in dimethylsulfoxide (20 ml) was allowed to stir for 12 hours at 90°C. The reaction mixture was poured into water (100 ml) and extracted with methylene chloride (3 x 100 ml). The organic layer was washed with water (3 x 150 ml), dried over anhydrous sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography (10% methanol-methylene chloride) afforded 0.15 g (34%) of product as a brown oil.
The oxalate salt was prepared in ethanol: mp 188-189°C Elemental analysis for C19H21FN2O2 «C2H2O4 «0.25H2O Calc'd C, 59.04; H, 5.63; N, 6.62
Found: C, 59.68; H, 5.49; N, 6.56
EXAMPLE 5
[3-(5-Fluoro-lH-indol-3-yl)propyl]-[2-(lH-indol-4-yloxy)-ethyl]-amine
A solution of 2-(lH-indol-4-yloxy)ethylchloride (0.7 g, 3.6 mmol), 5-fluoro- indolyl-3-propylamine (1.0 g, 5.4 mmol) in dimethylsulfoxide (20 ml) was allowed to stir for 12 hours at 90°C. The reaction mixture was poured into water (100 ml) and extracted with methylene chloride (3 x 100 ml). The organic layer was washed with - 33 - water (3 x 150 ml), dried over anhydrous sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography (5%-10% methanol-methylene chloride) afforded 0.54 g (43%) of product as a white solid: mp 70-73°C. The oxalate salt was prepared in ethanol: mp 183.5-185°C Elemental analysis for C21H22FN3O»C2H2O4
Calc'd C, 62.53; H, 5.48; N, 9.51
Found: C, 62.31; H, 5.38; N, 9.35
[2-(lH-IndoI-4-yloxy)ethyI]-[3-(lH-indol-3-yl)-propyl]amine (5b) This compound was prepared in the manner described above for Example 5 using 2-(lH-indol-4-yloxy)ethylchloride and 3-indolyl-propylamine in 65% yield as an off-white solid: mp 109-111 °C. The oxalate salt was prepared in isopropanol: mp 200.5-202°C.
Elemental analysis for C21H23N3O»C2H2O4 Calc'd: C, 65.19; H, 5.95; N, 9.92
Found: C, 64.89, H, 6.00; N, 9.81
[3-(lH-IndoI-3-yI)butyI]-[2-(lH-indol-4-yloxy)ethyI]amine (5c) This compound was prepared in the manner described above for Example 5 using 2-(lH-indol-4-yloxy)ethylchloride and 3-indolyl-butylamine in 43% yield as an off-white solid: mp 70-73°C.
The oxalate salt was prepared in ethanol: mp 183.5-185°C. Elemental analysis for C22H25N3O«C2H2O4
Calc'd: C, 62.58; H, 5.48; N, 9.52 Found: C, 62.31; H, 5.38; N,9.35
EXAMPLE 6 [2-(2,3-Dihydrobenzo[l,4]dioxin-5-yloxy)-ethyl]-[2-(lH-indol-3-yI)- ethyl]amine A solution of 2-(2,3-dihydrobenzo[l,4]dioxin-5-yloxy) ethylamine (0.38 g, 1.9 mmol), 3-(2-bromoethyl)-indole (0.24 g, 1.1 mmol) and triethylamine (0.22 g, 2.2 mmol) in anhydrous dimethylsulfoxide (20 ml) was allowed to stir for 14 hours at 90°C. The mixture was poured into water (100 ml) and extracted with methylene chloride (3 x 100 ml). The organic layer was washed with water (3 x 150 ml), dried over anhydrous sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography (10% methanol-methylene choride plus ammonium hydroxide) afforded 0.19 g (52%) as a yellow oil. - 34 -
The oxalate salt was prepared in ethanol: mp 197.5-198.5°C Elemental analysis for C20H22N2O3»C2H2O4
Calc'd: C, 61.63; H, 5.64; N, 6.53
Found: C, 61.36; H, 5.46; N, 6.45s
EXAMPLE 7
[2-(2,3-Dihydro-benzo[l,4]dioxin-5-yloxy)-ethyl]-[3-(5-fluoro-lH- indoI-3-yl)-propyI]-amine
A solution of 5-(2-chloroethoxy)-(2,3)-dihydrobenzo [l,4]dioxane (0.75 g, 3.5 mmol), 3-(5-fluoro-lH-indol-3-yl)-propylamine (1.0 g, 5.2 mmol) and triethylamine
(0.35 g, 3.5 mmol) in anhydrous dimethylsulfoxide (20 ml) was allowed to stir for 14 hours at 100°C. The mixture was poured into water (100 ml) and extracted with methylene chloride (3 x 100 ml). The organic layer was washed with water (3 x 150 ml), dried over anhydrous sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography (5% -10% methanol-methylene choride plus ammonium hydroxide) afforded 0.10 g (52%) of product as a yellow oil.
The fumarate salt was prepared in isopropanol: mp 189.5-190.5°C
Elemental analysis for C21H23FN2O3 »0.5C4H4O4 «0.5H2O Calc'd: C, 64.74; H, 5.88; N, 6.54 Found: C, 64.01; H, 5.95; N, 6.36
EXAMPLE 8 [2-(6-Fluorochroman-8-yloxy)ethyl]-[2-(lH-indol-3-yl)ethyl]-amine
A solution of 2-(6-fluorochroman-8-yloxy)ethylchloride (0.41 g, 2.2 mmol), 3- (2-bromoethyl)indole (0.25 g, 1.1 mmol) and triethylamine (0.23 g, 2.2 mmol) in anhydrous dimethylsulfoxide (20 ml) was allowed to stir for 12 hours at 90°C. The mixture was poured into water (100 ml) and extracted with methylene chloride (3 x 100 ml). The organic layer was washed with water (3 x 150 ml), dried over anhydrous sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography (10% methanol-methylene choride plus ammonium hydroxide) afforded 0.15 g (34%) of product as a yellow oil.
The oxalate salt was prepared in ethanol: mp 213-214°C
Elemental analysis for C21H23FN2O2 »C2H2O4
Calc'd: C, 62.11 ; H,5.67; N, 6.30 Found: C, 62.26; H, 5.71; N, 6.19 - 35 -
EXAMPLE 9
[2-(6-Fluorochroman-8-yloxy)ethyl]-[3-(5-fluro-lH-indol-3-yl)propyl]- amine (9a)
A solution 2-(6-fluorochroman-8-yloxy)ethylchloride (0.25 g, 7.1 mmol), 3-(5- fluoro-lH-indol-3-yl)-propylamine (0.42 g, 2.2 mmol) and triethylamine (0.22 g, 2.2 mmol) in anhydrous dimethylsulfoxide (20 ml) was allowed to stir for 14 hours at
90°C. The mixture was poured into water (100 ml) and extracted with methylene chloride (3 x 100 ml). The organic layer was washed with water (3 x 150 ml), dried over anhydrous sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography (10% methanol-methylene choride plus ammonium hydroxide) afforded 0.25 g (60%) as a white solid: mp 137-138.5°C.
The oxalate salt was prepared in isopropanol: mp 214-215°C
Elemental analysis for C22H24F2N2O2 »1.5C2H2O4 Calc'd: C, 57.58; H, 5.22; N, 5.31 Found: C, 57.75; H, 5.07; N, 5.51
[2-(6-Fluorochroman-8-yloxy)ethyl]-[2-(5-fluro-lH-indol-3-yl)ethyI]- amine (9b)
A solution of 2-(6-fluorochroman-8-yloxy)ethylchloride (0.26 g, 1.1 mmol), 2- (5-fluoro-lH-indol-3-yl)-ethylamine (0.45 g, 2.1 mmol) and triethylamine (0.30 ml,
2.1 mmol) in anhydrous dimethylsulfoxide (20 ml) was allowed to stir for 14 hours at
90°C. The mixtrue was poured into water (100 ml) and extracted with methylene chloride (3 x 100 ml). The organic layer was washed with water (3 x 150 ml), dried over anhydrous sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography (10% methanol-methylene choride plus ammonium hydroxide) afforded 0.19 g (48%) of product as a yellow oil.
The oxalate salt was prepared in ethanol: mp 201-203°C
Elemental analysis for C2!H22F2N2O2 »lC2H2O4
Calc'd: C, 59.70; H, 5.23; N, 6.05 Found: C, 59.48; H, 5.08; N, 5.88
EXAMPLE 10 [2-(2,3-Dihydrobenzofuran-7-yloxy)ethyl]-[3-(5-fluoro-lH-indol-3- yI)propyl]amine A solution of 2-(2,3-dihydrobenzofuran-7-yloxy)ethylchloride (0.38 g, 1.9 mmol), 3-(5-fluoro-lH-indol-3-yl)propylamine (0.93 g, 4.8 mmol), triethylamine - 36 -
(0.48 g, 4.8 mmol) in anhydrous DMSO (20 ml) was allowed to stir at 90°C for 12 hours. The mixture was poured into water (100 ml) and extracted with methylene chloride (3 x 100 ml). The organic layer was washed with water (3 x 150 ml), dried over anhydrous sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography (10% methanol-methylene chloride plus ammonium hydroxide) afforded 0.52 g (77%) of product as a yellow oil. The oxalate salt was prepared in ethanol: mp 158-160°C Elemental analysis for C21H23FN2O2 »C2H2O4
Calc'd: C, 63.82; H, 5.78; N, 5.95 Found: C, 63.45; H, 5.74; N,5.76
EXAMPLE 11
[2-(Benzofuran-7-yloxy)ethyI]-[3-(5-fluoro-lH-indoI-3-yl)propyl]amine
A solution of 2-(benzofuran-7-yloxy)-ethylchloride (0.58 g, 2.9 mmol), 3-(5- fluoro-lH-indol-3-yl)propylamine (1.4 g, 7.4 mmol) and triethylamine (0.74 g, 7.4 mmol) in anhydrous DMSO (20 ml) was allowed to stir at 90°C for 12 hours. The mixture was poured into water (100 ml) and extracted with methylene chloride (3 x 100 ml). The organic layer was washed with water (3 x 150 ml), dried over anhydrous sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography (7% methanol-methylene chloride) afforded 0.31 g (30%) of product as a light-brown oil.
The oxalate salt was prepared in THF: mp 181-183 °C
Elemental analysis for C21H2]FN2O2 »lC2H2O4
Calc'd: C, 62.39; H, 5.24; N, 6.33 Found: C, 62.07; H, 5.24; N, 6.45
EXAMPLE 12 [2-(5-Fluoro-2,3-dihydro-7-yloxy)-ethyI]-[2-(5-fluro-lH-indoI-3-yl)- ethyl]-amine A solution of 2-(5-fluoro-2,3-dihydrofuran-7-yloxy) ethylamine (0.40 g, 2.1 mmol), 2-(5-fluoro-lH-indol-3-yl)-ethylamine (0.25 g, 1.0 mmol) and triethylamine (0.29 ml, 2.1 mmol) in anhydrous dimethylsulfoxide (20 ml) was allowed to stir for 14 hours at 90°C. The mixture was poured into water (100 ml) and extracted with methylene chloride (3 x 100 ml). The organic layer was washed with water (3 x 100 ml), dried over anhydrous sodium sulfate, filtered and the solvent was removed under - 37 - vacuum. Chromatography (5% methanol-methylene choride plus ammonium hydroxide) afforded 0.2 g (54%) of product of product as a yellow oil. The oxalate salt was prepared in ethanol: mp 209.5-210.5°C Elemental analysis for C20H20F2N2O2 »1.5C2H2O4 Calc'd: C, 55.98; H, 4.70; N, 5.68
Found: C, 55.53; H, 4.44; N, 5.72
EXAMPLE 13 [3-(5-Fluoro-lH-indol-3-yl)-propyl]-[2-(indan-4-yloxy)-ethyl] -amine (13a)
A solution of 2-(indan-4-yloxy)-ethylchloride (0.58 g, 2.9 mmol), 3-(5-fluoro- lH-indol-3-yl)-propylamine (1.4 g, 7.4 mmol) and triethylamine (1 ml, 7.4 mmol) in anhydrous dimethylsulfoxide (20 ml) was allowed to stir for 12 hours at 90°C. The mixture was poured into water (100 ml) and extracted with methylene chloride (3 x 100 ml). The organic layer was washed with water (3 x 100 ml), dried over anhydrous sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography (7% methanol-methylene choride) afforded 0.31 g (30%) of product as a brown oil. The oxalate salt was prepared in tetrahydrofuran: mp 220-222°C Elemental analysis for C22H25FN2O»C2H2O4 Calc'd: C, 65.10; H, 6.15; N, 6.33
Found: C, 64.74; H, 6.14; N, 6.11
[3-(5-Fluoro-lH-indoI-3-yl)-propyl]-[2-(5,6,7,8-etrahydro-naphthalen- l-yloxy)-ethyl]-amine (13b) This compound was prepared in the manner described above for Examle 13 by replacing 2-(indan-4-yloxy)-ethylchloride with 2-(5,6,7,8-tetrahydronapthalen-l-yloxy) -ethylchloride (0.6 g, 2.8 mmol) in 29% yield (0.3 g) as a yellow oil. The fumarate salt was prepared in ethanol: mp 203-205°C Elemental analysis for C23H27FN2O«0.5C4H4O4 Calc'd: C, 70.73; H,6.89; N, 6.60
Found: C, 70.49; H, 6.87; N, 6.52
[3-(lH-indol-3-yI)-propyl]-[2-(naphthalen-l-yloxy)-ethyl]-amine (13c) This compound was prepared in the manner described above for Example 13 by replacing 2-(indan-4-yloxy)-ethylchloride with 2-(napthalen-l-yloxy)-ethylchloride (0.6 g, 2.8 mmol), and 3-(5-fluoro-lH-indol-3-yl)-propylamine with 3-(lH-indol-3- - 38 - yl)-propylamine (1.35 g, 7.2 mmol) in 85% yield (1.42 g) as a yellow solid: mp 119- 120°C.
The fumarate salt was prepared in ethanol: mp 203-205°C Elemental analysis for C23H24N2O»0.5C4H4O4«0.25H2O Calc'd: C, 73.78; H,6.56; N, 6.88
Found: C, 73.74; H,6.47; N, 6.89
[3-(lH-indol-3-yI)-propyl]-[2-phenoxy-ethyl]-amine (13d)
This compound was prepared in the manner described above for Example 13 by replacing 2-(napthalen-l-yloxy)-ethylchloride with 2-phenoxy-ethylchloride (0.59 g, 3.8 mmol) in 100% yield (1.08 g) as a yellow oil. The fumarate salt was prepared in ethanol: mp 203-205°C Elemental analysis for C19H22N2O»C4H4O4
Calc'd: C, 67.30; H, 6.38; N, 6.82 Found: C, 67.01; H, 6.30; N, 6.73
EXAMPLE 14 [3-(5-Fluoro-lH-indoI-3-yloxy)-proyl]-[2-(indan-5-yloxy)-ethyl]-amine
A solution of 2-(indan-5-yloxy)-ethylchloride (0.7 g, 3.5 mmol), 3-(5-fluoro- lH-indol-3-yl)-propylamine (1.01 g, 5.3 mmol) and triethylamine (0.53 g, 5 mmol) in anhydrous dimethylsulfoxide (20 ml) was allowed to stir for 12 hours at 90°C. The mixture was poured into water (100 ml) and extracted with methylene chloride (3 x 100 ml). The organic layer was washed with water (3 x 100 ml), dried over anhydrous sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography (5-10% methanol-methylene choride) afforded 0.53 g (43%) of product as a yellow oil. The fumarate salt was prepared in ethanol: mp 179-180°C Elemental analysis for C22H25FN2O»0.5C4H4O4
Calc'd: C, 69.46; H, 6.68; N, 6.75
Found: C, 69.19; H, 6.67; N, 6.72
EXAMPLE 15
[3-(lH-Indol-3-yl)-propyl]-[2-(quinolin-8-yloxy)ethyl]-amine
To a solution of (2-hydroxy-ethyl)-[3-(lH-indol-3-yl)-propyl]- carbamic acid- tert-butyl ester (0.86 g, 2.7 mmol), triphenylphosphine (0.71 g, 2.7 mmol) and 8- hydroxy-quinoline (0.26 g, 2.7 mmol) in tetrahydrofuran (50 ml) was slowly added diisopropyl azodicarboxylate (0.55 g, 2.7 mmol). The reaction was stirred at room - 39 - temperature for 3 hours. Tetrahydrofuran was removed under vacuum. Chromatography (5 % methanol-methylene chloride) afforded a yellow solid, which was dissolved in methylene chloride (30 ml). To this solution was added a trifluoroacetic acid solution (4 ml in 10 ml methylene chloride). The reaction mixtrure was allowed to stir for 2 h at room temperature. The mixture was then quenched with saturated sodium carbonate and extracted with methylene chloride (3 x 100 ml). The organic layer was dried over anhydrous sodium sulfate and filtered. The solvent was removed under vacuum. Chromatography (10-15% methanol-methylene plus ammonium hydroxide) afforded 0.17 g (18%) of product as a light-yellow oil. The HC1 salt was prepared in ethyl acetate: mp 83-86°C Elemental analysis for C22H23N3O*HCM.25H2O
Calc'd: C, 65.34; H, 6.60; N, 10.39
Found: C, 65.24; H, 6.69; N, 10.47
EXAMPLE 16
[3-(5-Fluoro-lH-indol-3-yl)-propyl]-[2-(2-methoxy-phenoxy)-2-phenyl- ethyl]-amine
A solution of 2-(2-methoxy-phenoxy)-2-phenyl-ethylchloride (0.71 g, 2.7 mmol), 2-(5-fluoro-lH-indol-3-yl)-ethylamine (1.04 g, 5.4 mmol) and triethylamine (0.75 ml, 5.4 mmol) in anhydrous dimethylsulfoxide (20 ml) was allowed to stir for 12 hours at 90°C. The mixture was poured into water (100 ml) and extracted with methylene chloride (3 x 100 ml). The organic layer was washed with water (3 x 100 ml), dried over anhydrous sodium sulfate, filtered, and the solvent was removed under vacuum. Chromatography (7% methanol-methylene choride plus ammonium hydroxide) afforded 0.15 g (13%)of parouduct of product as a yellow oil. The citrate salt was prepared in ethyl ether: mp 64.5-67°C Elemental analysis for C20H20F2N2O2 #C6H8O7»1.5H2O Calc'd: C, 60.27; H, 6.01; N, 4.39
Found: C, 59.96; H, 6.00; N, 4.39
EXAMPLE 17
[3-(5-Fluoro-lH-indol-3-yl)-propyl]-[2-(2-methoxy- phenoxy)propyI]amine
A solution of 2-(2-methoxy-phenoxy)propylamine (0.26 g, 1.2 mmol), 5- fluoro-3-(3-p-toluenesulfonyloxypropyl)indole (0.26 g, 0.81 mol) and triethylamine
(0.13 g, 1.2 mmol) in anhydrous dimethylsulfoxide (20 ml) was allowed to stir for 8 - 40 - hours at 90°C. The mixture was poured into water (100 ml) and extracted with methylene chloride (3 x 100 ml). The organic layer was washed with water (3 x 100 ml), dried over anhydrous sodium sulfate, filtered and the solvent was removed under vacuum. Chromatography (10% methanol-methylene chloride plus ammonium hydroxide) afforded 0.1 g (36%) of product of product as a yellow oil. The oxalate salt was prepared in 1 -propanol: mp 143-146°C Elemental analysis for C20H20F2N2O2 »C2H2O4» 1 H2O
Calc'd: C, 59.47; H, 6.29; N, 6.03
Found: C, 59.34; H, 5.87; N, 5.96
The activity of the present compounds is demonstrated by the following standard pharmacological test procedures.
The PCR cloning of the human 5-HT1A receptor subtype from a human genomic library has been described previously Chanda et al., Mol. Pharmacol.. 43:516 (1993). A stable Chinese hamster ovary cell line expressing the human 5-HT1A receptor subtype (5-HT1A.CHO cells) was employed throughout this study. Cells were maintained in DMEM supplemented with 10% fetal calf serum, non-essential amino acids and penicillin/ streptomycin.
Cells were grown to 95-100% confluency as a monolayer before membranes were harvested for binding studies. Cells were gently scraped from the culture plates, transferred to centrifuge tubes, and washed twice by centrifugation (2000 rpm for 10 min., 4°C) in buffer (50 mM Tris; pH 7.5). The resulting pellets were aliquoted and placed at -80°C. On the day of assay, the cells were thawed on ice, and resuspended in buffer. Studies were conducted using [3H]8-OH-DPAT as the radioligand. The binding assay was performed in 96 well microtiter plates in a final total volume of 250 μL of buffer. Competition experiments were performed by using 7 concentrations of unlabelled drug and a final ligand concentration of 1.5 nM . Non-specific binding was determined in the presence of 10 μM 5HT. Saturation analysis was conducted by using [3H]8-OH-DPAT at concentrations ranging from 0.3-30 nM. Following a 30 minute incubation at room temperature, the reaction was terminated by the addition of ice cold buffer and rapid filtration using a M-96 Brandel Cell Harvester (Gaithersburg, MD) through a GF/B filter presoaked for 30 minutes in 0.5% polyethyleneimine. - 41 -
A protocol similar to that used by Cheetham et al., Neuropharmacol. 32:737, (1993) was used to determine the affinity of compounds for the serotonin transporter. Briefly, frontal cortical membranes prepared from male Sprague-Dawley rats were incubated with 3H-paroxetine (0.1 nM) for 60 min at 25°C. All tubes also contained either vehicle, test compound (one to eight concentrations), or a saturating concentration of fluoxetine (10 μM) to define specific binding. All reactions are terminated by the addition of ice cold Tris buffer followed by rapid filtration using a Tom Tech filtration device to separate bound from free 3H-paroxetine. Bound radioactivity was quantitated using a Wallac 1205 Beta Plate® counter. Nonlinear regression analysis was used to determine IC50 values which were converted to Ki values using the method disclosed in Cheng and Prusoff, Biochem. Pharmacol.. 22:3099, (1973); Ki = IC50/((Radioligand conc.)/(l + KD)).
The [35S]-GTPγS binding assay was similar to that disclosed by Lazareno and Birdsall, Br. J. Pharmacol.. 109: 1120, (1993). Briefly, 5-HT1A cloned receptor membrane fragments (as used for 5-HT1A receptor binding assays) were stored at -70 °C until needed. When needed, membranes were rapidly thawed, centrifuged at 40,000 x g for 10 minutes and resuspended at 4 °C for 10 minutes in assay buffer (25 mM HEPES, 3 mM MgCl2, 100 mM NaCI, 1 mM EDTA, 10 uM GDP, 500 mM DTT, pH 8.0). These membranes were then incubated for 30 min at 30 °C with [35S]GTPgS (1 nM) in the presence of vehicle, test compound (one to eight concentrations), or excess 8-OH-DPAT to define maximum agonist response. All reactions were terminated by the addition of ice cold Tris buffer followed by rapid filtration using a Tom Tech® filtration device to separate bound [35S]GTPgS from free compound. Agonists produce an increase in the amount of bound [ 5S]GTPgS whereas antagonists produce no increase in binding. Bound radioactivity was counted and analyzed as above.
The following assays were performed by incubating the cells with DMEM containing 25 mM HEPES, 5 mM theophylline and 10 μM pargyline for a period of 20 minutes at 37°C. Functional activity was assessed by treating the cells with forskolin (1 uM final concentration) followed immediately by test compound (6 concentrations) for an additional 10 min at 37°C. In separate experiments, 6 concentrations of antagonist were preincubated for 20 min prior to the addition of 10 nM 8-OH-DPAT and forskolin. The reaction was terminated by removal of the media and addition of 0.5 ml -42- ice cold assay buffer. Plates were stored at -20°C prior to assessment of cAMP formation by a cAMP SPA assay (Amersham).
The compounds tested correspond to those prepared in Examples 1 to 17 above. The results of the procedure are set forth in Table 1.
TABLE 1
Example 5-HT1A ST(Ki,nM,or GTPγS ED50 cAMP ED50 No. (Ki,nM) %[email protected]) (EMax%) (EMax%) la 1.97 22 13.0 (80 %) 1.32 (94%) lb 7.72 25 44.0 (60 %)
2 1.34 0.48 41.6 (77 %) 4.28 (97%)
3a 35.0 0.97 — 4.71 (99%)
3b 47.9 49 % (100)% —
4 91.4 28.0 — —
5a 1.50 0.57 2.0 (90 %) —
5b 2.47 14 4.0 (66 %) —
5c 4.22 18 25.8 (59%) —
6 5.80 12.0 (100 %) —
7 0.68 0.08 15.7 (75 %) 1.11(90 %)
8 8.53 4.5 36 (49%) —
9a 26.6 0.84 121 (0%) 49 (0%)
9b 29.2 4.5 — 234 (0%)
10 1.63 0.74 4.72 (80%) —
11 1.55 3.03 2.93 (99.9%) —
12 35.1 12.0 — —
13a 76.9 71 % — —
13b 170.3 40 — —
13c 16.8 34% — —
13d 9.20 26 % — —
14 158.4 56 — —
15 0.54 24 3.0 (76 %) —
16 43.9 21.0 — —
Figure imgf000044_0001
17 14.50 16.0 236 (97.5%) — - 43 -.
As demonstrated by the results set forth above, the compounds of the present invention are active towards 5HT1 A receptors and generally elevate serotonin levels by inhibiting 5-HT transport. Accordingly, the present compounds should be useful in treating disorders related to defects in serotonin concentration.
The compounds of this invention may be administered orally or parenterally, neat or in combination with conventional pharmaceutical carriers. Applicable solid carriers can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents or an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Any of the solid carriers known to those skilled in the art may be used with the compounds of this invention. Particularly suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins.
Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups and elixirs of the compounds of this invention. The compounds of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo- regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above, e.g., cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g., glycols) and their derivatives and oils (e.g., fractionated coconut oil and arachis oil). For parenteral administration, the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used to prepare compositions for parenteral administration. - 44 -
Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Compositions for oral administration may be either in liquid or solid composition form.
Preferably, the pharmaceutical compositions containing the compounds of this invention are in unit dosage form, e.g., tablets or capsules. In such form, the compositions may be sub-divided in unit doses containing appropriate quantities of the present compounds. The unit dosage forms can be packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. Alternatively, the unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.
The therapeutically effective amount of the compounds of this invention that is administered and the dosage regimen depends on a variety of factors, including the weight, age, sex, and medical condition of the subject, the severity of the disease, the route and frequency of administration, and the specific compound employed, and thus may vary widely. However, it is believed that the pharmaceutical compositions may contain the compounds of this invention in the range of about 0.1 to about 2000 mg, preferably in the range of about 0.5 to about 500 mg and more preferably between about 1 and about 100 mg. Projected daily dosages of active compound are about 0.01 to about 100 mg/kg body weight. The daily dose can be conveniently administered two to four times per day.
The present invention may be embodied in other specific forms without departing from the spirit and essential attributes thereof and accordingly, reference should be made to the appended claims, rather than to the foregoing specification, as indicating the scope of the invention.

Claims

45
WHAT IS CLAIMED IS:
A compound of the formula:
(CH2)n
Figure imgf000047_0001
Figure imgf000047_0002
wherein:
Rj is hydrogen, lower alkyl or aryl;
R2 is hydrogen, lower alkyl, phenyl or substituted phenyl;
X and Y are each, independently, hydrogen, lower alkyl, lower alkoxy, or halogen, or together combine with the carbon atoms to which they are attached to complete a cyclopentyl, cyclohexyl, phenyl, pyrrolyl, pyranyl, pyridinyl, dihydrofuranyl, furanyl, dioxanyl, oxazolyl or isoxazolyl group;
Z is hydrogen, halogen or lower alkoxy; with the proviso that when X, Y or Z represent lower alkoxy, they are not present at the ortho position; W is hydrogen, halogen, lower alkyl, cyano or a trifluoromethyl group; and n is 2-5; or pharmaceutically acceptable salts thereof.
2. A compound as in claim 1 , wherein:
Rj is hydrogen, methyl or aryl;
R2 is hydrogen;
X and Y are each, independently, hydrogen, halogen or lower alkoxy, or together combine with the carbon atoms to which they are attached to complete a cyclopentyl, cyclohexyl, phenyl, pyridinyl, dioxanyl, oxazolyl, furanyl or dihydrofuranyl group;
Z is hydrogen, halogen or lower alkoxy; with the proviso that when X, Y or Z represent lower alkoxy, they are not present at the ortho position;
W is hydrogen or halogen; and n is 2-4; or pharmaceutically acceptable salts thereof. - 46 -
3. The compound of claim 1, which is [3-(5-Fluoro-lH-indol-3-yl)-propyl]-[2- ( lH-indol-4-yloxy)-ethyl]-amine.
4. The compound of claim 1, which is [2-(lH-Indol-4-yloxy)ethyl]-[3-(lH-indol- 3-yl)-propyl]-amine.
5. The compound of claim 1, which is [3-(lH-Indol-3-yl)-butyl]-[2-(lH-indol-4- yloxy)-ethyl]-amine.
6. The compound of claim 1, which is [2-(2,3-Dihydro-benzo[l,4]dioxin-5- yloxy)-ethyl]-[2-(lH-indol-3-yl)-ethyl]-amine.
7. The compound of claim 1, which is [2-(2,3-Dihydro-benzo[l,4]dioxin-5- yloxy)-ethyl]-[3-(5-fluoro-lH-indol-3-yl)-propyl]-amine.
8. The compound of claim 1, which is [2-(6-Fluorochroman-8-yloxy)-ethyl]-[2- ( 1 H-indol-3-yl)-ethyl] -amine.
9. The compound of claim 1, which is [2-(6-Fluorochroman-8-yloxy)-ethyl]-[3- (5-fluoro-lH-indol-3-yl)-propyl]-amine.
10. The compound of claim 1, which is [2-(6-Fluorochroman-8-yloxy)-ethyl]-[2- (5-fluoro-lH-indol-3-yl)-ethyl]-amine.
11. The compound of claim 1, which is [2-(2,3-Dihydro-benzofuran-7-yloxy)- ethyl]-3-(5-fluoro-lH-indol-3-yl)-propyl]-amine.
12. The compound of claim 1, which is [2-(Benzofuran-7-yloxy)-ethyl]-[3-(5- fluoro- 1 H-indol-3-yl)-propyl]-amine.
13. The compound of claim 1, which is [2-(5-Fluoro-2,3-dihydro-benzofuran-7- yloxy)-ethyl]-[2-(5-fluoro-lH-indol-3-yl)-ethyl]-amine.
14. The compound of claim 1, which is [3-(5-Fluoro-lH-indol-3-yl)-propyl]-[2- (indan-4-yloxy)-ethyl]-amine. - 47 -
15. The compound of claim 1, which is [3-(5-Fluoro-lH-indol-3-yl)-propyl]-[2- (5,6,7, 8-tetrahydro-naphthalen-l-yloxy)-ethyl]-amine.
16. The compound of claim 1, which is [3-(lH-Indol-3-yl)-propyl]-[2-(naphthalen- l-yloxy)-ethyl] amine.
17. The compound of claim 1, which is [3-(lH-Indol-3yl)-propyl]-(2-phenoxy- ethyl)-amine.
18. The compound of claim 1, which is [3-(5-Fluoro-lH-indol-3yloxy)-propyl]-[2- (indan-5 -yloxy )-ethyl] -amine.
19. The compound of claim 1, which is [3-(lH-Indol-3-yl)-propyl]-[2-(quinolin-8- yloxy)-ethyl] -amine.
20. The compound of claim 1, which is [3-(5-Fluoro-lH-indol-3-yl)-propyl]-[2-(2- methoxy-phenoxy)-2-phenyl-ethyl]-amine.
21. The compound of claim 1, which is [3-(5-Fluoro-lH-indol-3-yl)-propyl]-[2-(2- methoxy-phenoxy)-propyl]amine.
22. A pharmaceutical composition comprising a compound of the formula:
χ- —
.NΓÇö (CH2)n
H'
Figure imgf000049_0001
wherein:
Rj is hydrogen, lower alkyl or aryl;
R2 is hydrogen, lower alkyl, phenyl or substituted phenyl;
X and Y are each, independently, hydrogen, lower alkyl, lower alkoxy, or halogen, or together combine with the carbon atoms to which they are attached to complete a cyclopentyl, cyclohexyl, phenyl, pyrrolyl, pyranyl, pyridinyl, dihydrofuranyl, furanyl, dioxanyl, oxazolyl or isoxazolyl group; - 48 -
Z is hydrogen, halogen or lower alkoxy; with the proviso that when X, Y or Z represent lower alkoxy, they are not present at the ortho position;
W is hydrogen, halogen, lower alkyl, cyano or a trifluoromethyl group; and n is 2-5; or pharmaceutically acceptable salts thereof.
23. A method for alleviating the symptoms of depression in a patient in need thereof comprising administering to said patient an antidepressant effective amount of a compound of the formula:
X-rΓÇö .
,NΓÇö (CH2)n
H'
wherein:
Ri is hydrogen, lower alkyl or aryl;
R2 is hydrogen, lower alkyl, phenyl or substituted phenyl;
X and Y are each, independently, hydrogen, lower alkyl, lower alkoxy, or halogen, or together combine with the carbon atoms to which they are attached to complete a cyclopentyl, cyclohexyl, phenyl, pyrrolyl, pyranyl, pyridinyl, dihydrofuranyl, furanyl, dioxanyl, oxazolyl or isoxazolyl group;
Z is hydrogen, halogen or lower alkoxy; with the proviso that when X, Y or Z represent lower alkoxy, they are not present at the ortho position;
W is hydrogen, halogen, lower alkyl, cyano or a trifluoromethyl group; and n is 2-5; or pharmaceutically acceptable salts thereof.
PCT/US1999/007621 1998-04-08 1999-04-07 N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents) WO1999051575A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002327359A CA2327359A1 (en) 1998-04-08 1999-04-07 N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents)
EP99915317A EP1070050A1 (en) 1998-04-08 1999-04-07 N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents)
JP2000542296A JP2002510675A (en) 1998-04-08 1999-04-07 N-aryloxyethyl-indolyl-alkylamines for treatment of depression (5-HT1A receptor activators)
AU33861/99A AU3386199A (en) 1998-04-08 1999-04-07 N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5725298A 1998-04-08 1998-04-08
US09/057,252 1998-04-08

Publications (1)

Publication Number Publication Date
WO1999051575A1 true WO1999051575A1 (en) 1999-10-14

Family

ID=22009457

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/007621 WO1999051575A1 (en) 1998-04-08 1999-04-07 N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents)

Country Status (6)

Country Link
EP (1) EP1070050A1 (en)
JP (1) JP2002510675A (en)
CN (1) CN1304403A (en)
AU (1) AU3386199A (en)
CA (1) CA2327359A1 (en)
WO (1) WO1999051575A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530319A (en) * 2000-02-11 2003-10-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Indol-3-yl derivatives
FR2845992A1 (en) * 2002-10-16 2004-04-23 Pf Medicament New cyclopentenyl benzyl and heteroaryl amines, useful in the treatment of schizophrenia, have an affinity for D2 and 5-HT1A receptors
WO2004074281A1 (en) * 2003-02-18 2004-09-02 Merck Patent Gmbh Benzofuran oxyethylamines serving as antidepressant drugs and anxiolytic drugs
WO2006061376A1 (en) * 2004-12-08 2006-06-15 Solvay Pharmaceuticals B.V. Aryloxyethylamine derivatives with a combination of partial d0pamine-d2 receptor agonism and serotonin reuptake inhibition
WO2003011210A3 (en) * 2001-07-31 2007-10-25 Astrazeneca Ab Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase
US7371769B2 (en) 2004-12-07 2008-05-13 Solvay Pharmaceuticals B.V. Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
US8101619B2 (en) 2004-12-08 2012-01-24 Solvay Pharmaceuticals B.V. Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10305739A1 (en) * 2003-02-11 2004-08-19 Merck Patent Gmbh New indolyl-substituted benzofuran derivatives, are 5-HT(1A) agonists and 5-HT reuptake inhibitors useful e.g. as anxiolytic, antidepressant, neuroleptic and/or antihypertensive agents

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3371098A (en) * 1966-11-29 1968-02-27 Philips Corp 5- and 6-methoxy-3-(phenoxyethyl-aminoethyl)-indoles
EP0025727A1 (en) * 1979-08-17 1981-03-25 Sanofi S.A. Indole derivatives, process for their preparation and medicaments containing them
EP0478954A1 (en) * 1990-08-29 1992-04-08 Merrell Pharmaceuticals Inc. Serotonin 5HT1A and 5HT1D antagonists
US5436264A (en) * 1993-08-19 1995-07-25 Syntex (U.S.A.) Inc. N-aryloxyalkyl tryptamine α1 -adrenergic receptor antagonists
WO1996026923A1 (en) * 1995-03-02 1996-09-06 Pierre Fabre Medicament Novel bi-tryptaminic derivatives, preparation process and utilization as drugs

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3371098A (en) * 1966-11-29 1968-02-27 Philips Corp 5- and 6-methoxy-3-(phenoxyethyl-aminoethyl)-indoles
EP0025727A1 (en) * 1979-08-17 1981-03-25 Sanofi S.A. Indole derivatives, process for their preparation and medicaments containing them
EP0478954A1 (en) * 1990-08-29 1992-04-08 Merrell Pharmaceuticals Inc. Serotonin 5HT1A and 5HT1D antagonists
US5436264A (en) * 1993-08-19 1995-07-25 Syntex (U.S.A.) Inc. N-aryloxyalkyl tryptamine α1 -adrenergic receptor antagonists
WO1996026923A1 (en) * 1995-03-02 1996-09-06 Pierre Fabre Medicament Novel bi-tryptaminic derivatives, preparation process and utilization as drugs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GLENNON R A: "CONCEPTS FOR THE DESIGN OF 5-HT1A SEROTONIN AGONISTS AND ANTAGONISTS", DRUG DEVELOPMENT RESEARCH, vol. 26, no. 3, 1 January 1992 (1992-01-01), pages 251 - 274, XP000562325, ISSN: 0272-4391 *
NELSON,D.L.: "Structure-Activity Relationships at 5-HT1A Recpeotrs: Binding Profiles and Intrinsic Activity", PHARMACOL.BIOCHEM.BEHAV., vol. 40, 1991, pages 1041 - 1051, XP002114414 *
SLEIGHT A J ET AL: "IDENTIFICATION OF 5-HYDROXYTRYPTAMINE1A RECEPTOR AGENTS USING A COMPOSITE PHARMACOPHORE ANALYSIS AND CHEMICAL DATABASE SCREENING", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, vol. 343, 1 January 1991 (1991-01-01), pages 109 - 116, XP000650292 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530319A (en) * 2000-02-11 2003-10-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Indol-3-yl derivatives
JP4938194B2 (en) * 2000-02-11 2012-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Indol-3-yl derivatives
WO2003011210A3 (en) * 2001-07-31 2007-10-25 Astrazeneca Ab Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase
US7163957B2 (en) 2002-10-16 2007-01-16 Pierre Fabre Medicament 3-(Cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia
JP2006508080A (en) * 2002-10-16 2006-03-09 ピエール、ファーブル、メディカマン 3- (Cyclopenten-1-yl) -benzyl- or 3- (cyclopenten-1-yl) -heteroarylmethylamine derivatives and their use as medicaments for treating schizophrenia
CN1319962C (en) * 2002-10-16 2007-06-06 皮埃尔法布雷医药公司 3-(cyclopenten-1-yl)-benzyl- or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia
US7235568B2 (en) 2002-10-16 2007-06-26 Pierre Fabre Medicament 3-(cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia
WO2004035561A1 (en) * 2002-10-16 2004-04-29 Pierre Fabre Medicament 3-(cyclopenten-1-yl)-benzyl- or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia
FR2845992A1 (en) * 2002-10-16 2004-04-23 Pf Medicament New cyclopentenyl benzyl and heteroaryl amines, useful in the treatment of schizophrenia, have an affinity for D2 and 5-HT1A receptors
WO2004074281A1 (en) * 2003-02-18 2004-09-02 Merck Patent Gmbh Benzofuran oxyethylamines serving as antidepressant drugs and anxiolytic drugs
US7425574B2 (en) 2003-02-18 2008-09-16 Merck Patent Gesellschaft Mit Beschrankter Haftung Benzofuran oxyethylamines as antidepressants and anxiolytics
AU2004213097B2 (en) * 2003-02-18 2010-06-24 Merck Patent Gmbh Benzofuran oxyethylamines serving as antidepressant drugs and anxiolytic drugs
US7371769B2 (en) 2004-12-07 2008-05-13 Solvay Pharmaceuticals B.V. Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
WO2006061376A1 (en) * 2004-12-08 2006-06-15 Solvay Pharmaceuticals B.V. Aryloxyethylamine derivatives with a combination of partial d0pamine-d2 receptor agonism and serotonin reuptake inhibition
US8101619B2 (en) 2004-12-08 2012-01-24 Solvay Pharmaceuticals B.V. Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition

Also Published As

Publication number Publication date
AU3386199A (en) 1999-10-25
JP2002510675A (en) 2002-04-09
EP1070050A1 (en) 2001-01-24
CA2327359A1 (en) 1999-10-14
CN1304403A (en) 2001-07-18

Similar Documents

Publication Publication Date Title
WO2006112464A1 (en) Piperazine-substituted benzothiophenes for treatment of mental disorders
CA2367681A1 (en) Azaindole derivatives for the treatment of depression
WO1999051575A1 (en) N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents)
EP1068184B1 (en) N-aryloxyethylamine derivatives for the treatment of depression
US6121307A (en) N-aryloxyethyl-indoly-alkylamines for the treatment of depression
EP1070063A1 (en) Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists)
EP1073651B1 (en) Indolyl derivatives as serotonergic agents
US20020128272A1 (en) 4,5,6, and 7-indole and indoline derivatives, their preparation and use
US6110956A (en) N-aryloxyethylamine derivatives for the treatment of depression
MXPA00009811A (en) N-aryloxyethyl-indoly-alkylamines for the treatment of depression (5-ht1a receptor active agents)
US6245780B1 (en) Tetrahydroisoquinolinyl-indole derivatives for the treatment of depression
US6162803A (en) Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression
US6337336B1 (en) Azaindole derivatives for the treatment of depression
EP1140919B1 (en) 1,4-disubstituted cyclohexane derivatives for the treatment of depression
US6489342B2 (en) Aryloxy piperidinyl indoles for treating depression
US6221863B1 (en) 3,4-dihydro-2H-benzo[1,4]oxazine derivatives
US6200994B1 (en) 1,4-Disubstituted cyclohexane derivatives for the treatment of depression
EP1068199B1 (en) N-aryloxyethyl-indoly-alkylamines for the treatment of depression
US6150533A (en) N-aryloxyethyl-indoly-alkylamines for the treatment of depression
US6313114B1 (en) 3,4-Dihydro-2H-benzo[1,4]oxazinyl-methyl)-[3-(1H-indol-3yl)-alkyl]- amines
MXPA00009807A (en) N-aryloxyethylamine derivatives for the treatment of depression
MXPA00012609A (en) 4,5,6 and 7-indole and indoline derivatives, their preparation and use
MXPA01006855A (en) New 1,4-disubstituted cyclohexane derivatives for the treatment of depression
MXPA01010677A (en) Azaindole derivatives for the treatment of depression
CA2370241A1 (en) Tetrahydroisoquinolinyl-indole derivatives for the treatment of depression

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99807013.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999915317

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2327359

Country of ref document: CA

Ref document number: 2327359

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 542296

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/009811

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1999915317

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999915317

Country of ref document: EP